| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|
| ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.72 | 0.684 | 33670440
|
| ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.72 | 0.684 | 33670440
|
| ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.72 | 0.684 | 35229723
|
| ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.72 | 0.684 | 25881239
|
| ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.72 | 0.684 | 25881239
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qRT-PCR followed by Western Blotting and IF staining | NA | 0.72 | 0.684 | 32396269
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay and SFA followed by RT-PCR and Western Blotting | NA | 0.72 | 0.684 | 27836546
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 32319573
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.72 | 0.684 | 30878308
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 25955300
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 28431267
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 29344850
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 31891569
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.72 | 0.684 | 28861158
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and ALDEFLUOR assay followed by Western Blotting | NA | 0.72 | 0.684 | 34163000
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by Western Blotting | NA | 0.72 | 0.684 | 29254164
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by Western Blotting and CFA | NA | 0.72 | 0.684 | 24928671
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.72 | 0.684 | 30737252
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | ALDEFLUOR assay followed by SFA and qRT-PCR | NA | 0.72 | 0.684 | 33784109
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay and qRT-PCR | NA | 0.72 | 0.684 | 32308544
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by FACs | NA | 0.72 | 0.684 | 25906011
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by Western Blotting | NA | 0.72 | 0.684 | 33924205
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 33980809
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 23583374
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 24247269
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 26517679
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 27836540
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 28198062
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 31207300
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 31263095
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.72 | 0.684 | 29235568
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Erlotinib | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 25125655
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 26278043
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 26278043
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Afatinib | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 30885551
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 30885551
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Osimertinib | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 30885551
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.72 | 0.684 | 28321046
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.72 | 0.684 | 28830450
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and ALDEFLUOR assay | NA | 0.72 | 0.684 | 29845263
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and ICC staining | NA | 0.72 | 0.684 | 31939436
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.72 | 0.684 | 34400945
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.72 | 0.684 | 34246759
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.684 | 33468994
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.684 | 34277782
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.72 | 0.684 | 26675547
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.684 | 29138851
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.72 | 0.684 | 32124474
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.72 | 0.684 | 27009878
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.72 | 0.684 | 33721187
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.72 | 0.684 | 33783940
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.72 | 0.684 | 33784109
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 33539684
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 34546848
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 35044041
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 35229723
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | ALDEFLUOR assay | NA | 0.72 | 0.684 | 23349823
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay | NA | 0.72 | 0.684 | 32655789
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.72 | 0.684 | 24607842
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.684 | 21600232
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.684 | 26779808
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 28406482
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 28400280
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 28850563
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Sorafenib | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 28850563
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 30555330
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 31466290
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 31582014
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 31928533
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 31928533
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 32033067
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 32401390
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 32612672
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay and Tumorigenicity assay | NA | 0.72 | 0.684 | 24013232
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.72 | 0.684 | 27035162
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.684 | 29416721
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.684 | 31121479
|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 22825470
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qRT-PCR followed by Western Blotting and IF staining | NA | 0.72 | 0.7582 | 32396269
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by qPCR and Western Blotting | NA | 0.72 | 0.7582 | 26782458
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs and IF staining followed by qRT-PCR | NA | 0.72 | 0.7582 | 31819528
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR and FACs followed by IF staining | NA | 0.72 | 0.7582 | 21947321
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | IHC staining and CFA followed by SFA and Western Blotting | NA | 0.72 | 0.7582 | 29299167
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting followed by ICC staining | NA | 0.72 | 0.7582 | 30341415
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | Western Blotting followed by IHC staining and SFA | NA | 0.72 | 0.7582 | 29299167
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.72 | 0.7582 | 33783940
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 33539684
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 25955300
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 28431267
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 30485693
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 31891569
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 32655789
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs and FACs followed by qRT-PCR | NA | 0.72 | 0.7582 | 28619508
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by FACs and qPCR | NA | 0.72 | 0.7582 | 26675547
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.72 | 0.7582 | 21520032
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and IF staining | NA | 0.72 | 0.7582 | 26239272
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and IF staining | NA | 0.72 | 0.7582 | 26261505
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and Western Blotting | NA | 0.72 | 0.7582 | 31263095
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by FACs and Western Blotting | NA | 0.72 | 0.7582 | 22370645
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.72 | 0.7582 | 28198062
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.72 | 0.7582 | 30737252
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting and FACs | NA | 0.72 | 0.7582 | 33125096
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining | NA | 0.72 | 0.7582 | 34527268
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IHC staining followed by MACs | NA | 0.72 | 0.7582 | 33887368
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining followed by SFA and FACs | NA | 0.72 | 0.7582 | 31024010
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by IF staining | NA | 0.72 | 0.7582 | 26690309
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by IF staining and CFA | NA | 0.72 | 0.7582 | 28000861
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by SFA and IF staining | NA | 0.72 | 0.7582 | 23456479
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and IF staining followed by FACs | NA | 0.72 | 0.7582 | 28534939
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR | NA | 0.72 | 0.7582 | 34400945
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.7582 | 29262597
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and RT-PCR followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.7582 | 29225473
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.72 | 0.7582 | 24356998
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by RT-PCR | NA | 0.72 | 0.7582 | 25783528
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.72 | 0.7582 | 25678473
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA and FACs | NA | 0.72 | 0.7582 | 25003810
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and FACs followed by qRT-PCR and Tumorigenicity assay | NA | 0.72 | 0.7582 | 29860718
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.72 | 0.7582 | 24101104
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.72 | 0.7582 | 30816208
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and RT-PCR | NA | 0.72 | 0.7582 | 23370278
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and RT-PCR | NA | 0.72 | 0.7582 | 23715514
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR and FACs | NA | 0.72 | 0.7582 | 26299367
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by Western Blotting | NA | 0.72 | 0.7582 | 33924205
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 33980809
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.72 | 0.7582 | 34803670
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.72 | 0.7582 | 33721187
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and Western Blotting | NA | 0.72 | 0.7582 | 29387193
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 23583374
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 24247269
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 27836540
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 31207300
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 32782570
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs and FACs followed by SFA | NA | 0.72 | 0.7582 | 28854941
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs and FACs followed by SFA | NA | 0.72 | 0.7582 | 30542415
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.72 | 0.7582 | 34246759
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 33437165
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 33468994
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 34832951
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 35044041
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.72 | 0.7582 | 24646078
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.72 | 0.7582 | 29144562
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.72 | 0.7582 | 26468775
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.72 | 0.7582 | 25906011
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed +Cisplatin | RT-PCR | NA | 0.72 | 0.7582 | 26895954
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.72 | 0.7582 | 31201845
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 29044153
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 29138851
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 30981768
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 30981768
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.72 | 0.7582 | 32124474
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 24961511
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 26546046
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 27009878
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 28787001
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 28951614
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 29414668
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.72 | 0.7582 | 27911857
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.72 | 0.7582 | 21347385
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.72 | 0.7582 | 22855139
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | CFA followed by FACs | NA | 0.72 | 0.7582 | 34816662
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.72 | 0.7582 | 33068069
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 27920206
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 33959615
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 34827096
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 35337095
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and SFA | NA | 0.72 | 0.7582 | 34063628
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs | NA | 0.72 | 0.7582 | 33631674
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 34349823
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 34424425
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.72 | 0.7582 | 35267489
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by FACs | NA | 0.72 | 0.7582 | 28406482
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs | NA | 0.72 | 0.7582 | 23349823
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 24440048
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 27542268
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 28484448
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 28516515
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 28789457
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 31352088
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 32466428
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and CFA | NA | 0.72 | 0.7582 | 32329414
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and Tumorigenicity assay | NA | 0.72 | 0.7582 | 27485114
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 24903381
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 26572130
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 26782458
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 27276704
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 28179999
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 29144562
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Dexamethasone+Pemetrexed | FACs followed by SFA | NA | 0.72 | 0.7582 | 29753869
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 31368411
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 31466290
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and CFA | NA | 0.72 | 0.7582 | 29845263
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.7582 | 21600232
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs | NA | 0.72 | 0.7582 | 24008862
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by SFA | NA | 0.72 | 0.7582 | 22900142
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Modified PLGA magnetic SFA followed by FACs | NA | 0.72 | 0.7582 | 29843871
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 20028869
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 20028869
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 24101104
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 25965829
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 28580971
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 31121479
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 32549341
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 32676335
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.72 | 0.7582 | 28202526
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and FACs | NA | 0.72 | 0.7582 | 19464919
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by FACs and Tumorigenicity assay | NA | 0.72 | 0.7582 | 20949018
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.72 | 0.7582 | 22825470
|
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.72 | 0.7582 | 25007054
|
| EPCAM | 11529 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.56 | 0.211 | 25881239
|
| EPCAM | 11529 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.56 | 0.211 | 25881239
|
| EPCAM | 11529 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.56 | 0.211 | 25881239
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining and RT-PCR | NA | 0.56 | 0.211 | 21738704
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.56 | 0.211 | 33539684
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and IF staining followed by FACs | NA | 0.56 | 0.211 | 28534939
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.56 | 0.211 | 25678473
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.56 | 0.211 | 28854941
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR and FACs | NA | 0.56 | 0.211 | 26299367
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.56 | 0.211 | 27766570
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.56 | 0.211 | 22855139
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.56 | 0.211 | 33995625
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.56 | 0.211 | 33670440
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.56 | 0.211 | 34277782
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Tumorigenicity assay | NA | 0.56 | 0.211 | 33707423
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and FACs followed by SFA and Tumorigenicity assay | NA | 0.56 | 0.211 | 29017078
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.56 | 0.211 | 22498113
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.56 | 0.211 | 31692042
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Curcumin+Cisplatin | FACs followed by SFA | NA | 0.56 | 0.211 | 26531053
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.56 | 0.211 | 29868483
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and CFA | NA | 0.56 | 0.211 | 29845263
|
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.56 | 0.211 | 25881239
|
| THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining and RT-PCR | NA | 0.56 | 0.0371 | 21738704
|
| THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | IF staining followed by FACs and SFA | NA | 0.56 | 0.0371 | 31781681
|
| THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by RT-PCR and SFA | NA | 0.56 | 0.0371 | 29576613
|
| THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Tumorigenicity assay | NA | 0.56 | 0.0371 | 33707423
|
| THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.56 | 0.0371 | 24101104
|
| THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.56 | 0.0371 | 24101104
|
| POU5F1 | 9221 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.6448 | 35229723
|
| SOX9 | 11204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.0244 | 35229723
|
| SOX9 | 11204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.0244 | 29416721
|
| SOX9 | 11204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.0244 | 29416721
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | IF staining followed by Western Blotting | NA | 0.52 | 0.6448 | 34168463
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | 5-Fluorouracil | IF staining followed by Western Blotting | NA | 0.52 | 0.6448 | 34168463
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 34063628
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 33783940
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 33539684
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 34873829
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 35229723
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 28406482
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.6448 | 28179999
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 32319573
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.6448 | 30878308
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 28431267
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 29344850
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 29888108
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 30485693
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 32655789
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 28861158
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 30555330
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting and RT-PCR | NA | 0.52 | 0.6448 | 24333218
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.52 | 0.6448 | 21520032
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.6448 | 24101104
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and IF staining | NA | 0.52 | 0.6448 | 26239272
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining | NA | 0.52 | 0.6448 | 21124918
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.52 | 0.6448 | 29262597
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.52 | 0.6448 | 24356998
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.52 | 0.6448 | 28854941
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.52 | 0.6448 | 28534939
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by FACs and qRT-PCR | NA | 0.52 | 0.6448 | 29860718
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.52 | 0.6448 | 30816208
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.52 | 0.6448 | 33707423
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.52 | 0.6448 | 34163000
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 33980809
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 34949193
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.52 | 0.6448 | 34803670
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 33721187
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and Western Blotting | NA | 0.52 | 0.6448 | 26779808
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and Western Blotting | NA | 0.52 | 0.6448 | 29387193
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.52 | 0.6448 | 32637578
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 21425153
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 21802163
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 22370645
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 23583374
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 24013232
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 24386189
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 26517679
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29299167
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29299167
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29416721
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31207300
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31263095
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31928533
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 33125096
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SP assay followed by Western Blotting | NA | 0.52 | 0.6448 | 23022172
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.52 | 0.6448 | 23349823
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.52 | 0.6448 | 29254164
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting | NA | 0.52 | 0.6448 | 30341415
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.52 | 0.6448 | 31282010
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting followed by Migration assay | NA | 0.52 | 0.6448 | 20074550
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 29299167
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.52 | 0.6448 | 24668028
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.52 | 0.6448 | 26261505
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 33924205
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.52 | 0.6448 | 33068069
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.6448 | 33995625
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.6448 | 34400945
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.52 | 0.6448 | 33784109
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA | NA | 0.52 | 0.6448 | 33670440
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 33437165
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 33468994
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34209829
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34277782
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34832951
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 35044041
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 34681614
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29017078
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | qPCR | NA | 0.52 | 0.6448 | 26181204
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | qPCR | NA | 0.52 | 0.6448 | 26181204
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.6448 | 24646078
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.52 | 0.6448 | 29144562
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.52 | 0.6448 | 26468775
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.6448 | 22300949
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed +Cisplatin | RT-PCR | NA | 0.52 | 0.6448 | 26895954
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.6448 | 26940223
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.6448 | 26940223
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.6448 | 31201845
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by CFA | NA | 0.52 | 0.6448 | 29995950
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.6448 | 25003810
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.6448 | 29225473
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.6448 | 31368411
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Regorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Sorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.52 | 0.6448 | 26675547
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 22900142
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 24101104
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 27766570
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 28035349
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29044153
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29138851
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29448000
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 31024010
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 32401390
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 32612672
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 32655321
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 26546046
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 27009878
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28787001
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 31582014
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.52 | 0.6448 | 28456659
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 31871777
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.52 | 0.6448 | 23009336
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.52 | 0.6448 | 22615765
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.52 | 0.6448 | 22825470
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.52 | 0.6448 | 21947321
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Dexamethasone+Pemetrexed | FACs followed by SFA | NA | 0.52 | 0.6448 | 29753869
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by FACs and Tumorigenicity assay | NA | 0.52 | 0.6448 | 20949018
|
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.52 | 0.6448 | 26081992
|
| PRDX2 | 9353 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting followed by ICC staining | NA | 0.52 | 0.0074 | 30341415
|
| PRDX6 | 16753 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | IF staining followed by Western Blotting | NA | 0.52 | 0.0042 | 31819528
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 35278461
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 34063628
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 34065942
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 33783940
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 34873829
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 35229723
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 28406482
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.5695 | 28179999
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.5695 | 30878308
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qRT-PCR followed by Western Blotting | NA | 0.52 | 0.5695 | 32396269
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 25955300
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 29888108
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 30485693
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 32655789
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 30555330
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 22615765
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.52 | 0.5695 | 21520032
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and IF staining | NA | 0.52 | 0.5695 | 26239272
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.52 | 0.5695 | 24356998
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.52 | 0.5695 | 30816208
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.52 | 0.5695 | 33707423
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.52 | 0.5695 | 34163000
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 33980809
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 34949193
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 33721187
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and Western Blotting | NA | 0.52 | 0.5695 | 26779808
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.52 | 0.5695 | 32637578
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 21425153
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 21802163
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 22370645
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 24013232
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29299167
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29416721
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31207300
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31263095
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31658996
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31928533
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 33125096
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.52 | 0.5695 | 23349823
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.52 | 0.5695 | 29254164
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting | NA | 0.52 | 0.5695 | 30341415
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 29299167
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.52 | 0.5695 | 26261505
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 33924205
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.5695 | 33995625
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.5695 | 34400945
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 33784109
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 34246759
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA | NA | 0.52 | 0.5695 | 33670440
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 33437165
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34209829
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34277782
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34832951
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 34681614
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 29017078
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | qPCR | NA | 0.52 | 0.5695 | 26181204
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.5695 | 24646078
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 29144562
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.52 | 0.5695 | 26468775
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.5695 | 25906011
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.5695 | 26940223
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.5695 | 31201845
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by CFA | NA | 0.52 | 0.5695 | 29995950
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.5695 | 25003810
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.5695 | 31368411
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.5695 | 28850563
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Regorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.5695 | 28850563
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Sorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.5695 | 28850563
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.52 | 0.5695 | 26675547
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.52 | 0.5695 | 31796785
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 22900142
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 24101104
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 24101104
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | 5-Fluorouracil | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 25683371
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 25683371
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 27766570
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 28035349
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 29044153
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 29448000
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 31024010
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 32033067
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 32401390
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 32655321
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 23370278
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 26546046
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 27009878
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 29414668
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.52 | 0.5695 | 28456659
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 31871777
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.52 | 0.5695 | 23009336
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Trichostatin | SP assay followed by qRT-PCR | NA | 0.52 | 0.5695 | 27418136
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by SFA and RT-PCR | NA | 0.52 | 0.5695 | 28440478
|
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.52 | 0.5695 | 21947321
|
| SOX9 | 11204 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 0.0244 | 35278461
|
| VTCN1 | 28873 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 0.0021 | 35278461
|
| ABCG2 | 74 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.1739 | 25881239
|
| ABCG2 | 74 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.1739 | 25881239
|
| ABCG2 | 74 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Gene ChIP analysis | Up | 0.48 | 0.1739 | 18423378
|
| ABCG2 | 74 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.48 | 0.1739 | 18034892
|
| ALDH1A3 | 409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.48 | 0.0201 | 25881239
|
| ALDH1A3 | 409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.48 | 0.0201 | 25881239
|
| ALDH1A3 | 409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.0201 | 25881239
|
| ALDH1A3 | 409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.0201 | 25881239
|
| CD44 | 1681 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.48 | 1 | 35229723
|
| MCL1 | 6943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.48 | 0.0032 | 25881239
|
| MIR19A | 31574 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.48 | 0.0064 | 22301433
|
| SIRPG | 15757 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.48 | 0.0021 | 29416721
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 28861158
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting and qRT-PCR | NA | 0.48 | 0.1739 | 25200103
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting and SP assay followed by qRT-PCR | NA | 0.48 | 0.1739 | 23009336
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | MACs followed by Western Blotting | NA | 0.48 | 0.1739 | 31819528
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | 5-fluorouracil | FACs followed by qRT-PCR | NA | 0.48 | 0.1739 | 22416214
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Methotrexate | FACs followed by qRT-PCR | NA | 0.48 | 0.1739 | 22416214
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.48 | 0.1739 | 24356998
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SP assay followed by FACs and RT-PCR | NA | 0.48 | 0.1739 | 24009622
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and RT-PCR | NA | 0.48 | 0.1739 | 25988710
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.48 | 0.1739 | 33707423
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 33980809
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and Western Blotting | NA | 0.48 | 0.1739 | 31871777
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining followed by SP assay | NA | 0.48 | 0.1739 | 25810011
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by IHC staining and Tumorigenicity assay | NA | 0.48 | 0.1739 | 29552128
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.48 | 0.1739 | 33068069
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.48 | 0.1739 | 26468775
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.1739 | 31368411
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 22900142
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 24961511
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.48 | 0.1739 | 24961511
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1739 | 28951614
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1739 | 29414668
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.1739 | 27911857
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.1739 | 21347385
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.1739 | 22615765
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.1739 | 22855139
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.48 | 0.1739 | 26081992
|
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SP assay followed by FACs and Tumorigenicity assay | NA | 0.48 | 0.1739 | 22844424
|
| ALDH1A3 | 409 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0201 | 27836546
|
| ALDH1A3 | 409 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.48 | 0.0201 | 34163000
|
| ALDH1A3 | 409 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.48 | 0.0201 | 29235568
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1135 | 30555330
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting and RT-PCR | NA | 0.48 | 0.1135 | 24333218
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 0.1135 | 32637578
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 22370645
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 32726929
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 32782570
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | Western Blotting followed by SFA | NA | 0.48 | 0.1135 | 29299167
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 34681614
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 34681614
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1135 | 29138851
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 21520032
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 29414668
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 0.1135 | 21124918
|
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Dexamethasone+Pemetrexed | FACs followed by SFA | NA | 0.48 | 0.1135 | 29753869
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.48 | 1 | 34065942
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 1 | 25955300
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 1 | 28431267
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 1 | 32655789
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.48 | 1 | 21520032
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and FACs followed by Western Blotting | NA | 0.48 | 1 | 34163000
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.48 | 1 | 34949193
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and Western Blotting followed by SFA | NA | 0.48 | 1 | 28259998
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining | NA | 0.48 | 1 | 34527268
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | IF staining followed by FACs and SFA | NA | 0.48 | 1 | 31781681
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining followed by SFA and FACs | NA | 0.48 | 1 | 31024010
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by SFA and ICC staining | NA | 0.48 | 1 | 31939436
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR | NA | 0.48 | 1 | 34400945
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.48 | 1 | 28854941
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA and FACs | NA | 0.48 | 1 | 25003810
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 1 | 30816208
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by Western Blotting | NA | 0.48 | 1 | 33924205
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 33980809
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.48 | 1 | 35278461
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 1 | 32637578
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 23773734
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 24247269
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 27836540
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28198062
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28741092
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | SFA followed by Western Blotting | NA | 0.48 | 1 | 32726929
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 32782570
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 33125096
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.48 | 1 | 29254164
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.48 | 1 | 29552200
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ICC staining | NA | 0.48 | 1 | 31582014
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.48 | 1 | 23947765
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.48 | 1 | 26261505
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.48 | 1 | 34246759
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 33437165
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 34832951
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed +Cisplatin | RT-PCR | NA | 0.48 | 1 | 26895954
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.48 | 1 | 31201845
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qPCR followed by Tumorigenicity assay | NA | 0.48 | 1 | 31796785
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 1 | 24961511
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 29044153
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.48 | 1 | 32124474
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.48 | 1 | 24961511
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 1 | 28951614
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | CFA followed by FACs | NA | 0.48 | 1 | 34816662
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.48 | 1 | 33068069
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.48 | 1 | 33784109
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by SFA | NA | 0.48 | 1 | 33784109
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.48 | 1 | 34277782
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.48 | 1 | 35267489
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 1 | 29017078
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 22498113
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs | NA | 0.48 | 1 | 23349823
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 26278043
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 26278043
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 28516515
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 28789457
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 31352088
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 32466428
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and Tumorigenicity assay | NA | 0.48 | 1 | 27485114
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29144562
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Dexamethasone+Pemetrexed | FACs followed by SFA | NA | 0.48 | 1 | 29753869
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29868483
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and CFA | NA | 0.48 | 1 | 29845263
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.48 | 1 | 25965829
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.48 | 1 | 27035162
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.48 | 1 | 30555330
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.48 | 1 | 32655321
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.48 | 1 | 25881239
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by FACs and Tumorigenicity assay | NA | 0.48 | 1 | 20949018
|
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs | NA | 0.48 | 1 | 22825470
|
| EZH2 | 3527 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting and qRT-PCR followed by CFA and Migration Invasion assay | NA | 0.48 | 0.0074 | 29156731
|
| GLI1 | 4317 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0308 | 34424425
|
| HOXD8 | 5139 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.0011 | 27748920
|
| IKZF3 | 13178 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0032 | 30816208
|
| IL6 | 6018 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ELISA and qPCR followed by SFA and Migration Invasion assay | NA | 0.48 | 0.0191 | 26675547
|
| IL6 | 6018 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.48 | 0.0191 | 27009878
|
| JARID2 | 6196 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting and SFA | NA | 0.48 | 0.0032 | 34246759
|
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0891 | 34873829
|
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0891 | 28179999
|
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0891 | 30555330
|
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.48 | 0.0891 | 33995625
|
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.0891 | 33670440
|
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.48 | 0.0891 | 25906011
|
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.0891 | 28456659
|
| LIN28A | 15986 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0138 | 28179999
|
| LIN28A | 15986 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0138 | 29262597
|
| MCL1 | 6943 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 23418490
|
| MIR19A | 31574 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0064 | 28431267
|
| MIR19B1 | 31575 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 28431267
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 30485693
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 30555330
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 22615765
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 33980809
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 22370645
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1304 | 34681614
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.1304 | 29225473
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1304 | 32033067
|
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.1304 | 28456659
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 34063628
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 34065942
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 35229723
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28406482
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5461 | 28179999
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5461 | 32396269
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28431267
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 29344850
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 29888108
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 30485693
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 32655789
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 30555330
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting and RT-PCR | NA | 0.48 | 0.5461 | 24333218
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.48 | 0.5461 | 21520032
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.5461 | 29262597
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.48 | 0.5461 | 24356998
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.48 | 0.5461 | 28854941
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 0.5461 | 28534939
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by FACs and qRT-PCR | NA | 0.48 | 0.5461 | 29860718
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 0.5461 | 30816208
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR and FACs | NA | 0.48 | 0.5461 | 26299367
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.48 | 0.5461 | 33707423
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 33980809
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 34949193
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 35267489
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 33721187
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and Western Blotting | NA | 0.48 | 0.5461 | 26779808
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 29387193
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 0.5461 | 32637578
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 21425153
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 21802163
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 22370645
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 26517679
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 27836540
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 28198062
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29416721
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 31928533
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 32782570
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 33125096
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.48 | 0.5461 | 23349823
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting | NA | 0.48 | 0.5461 | 30341415
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.48 | 0.5461 | 26261505
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IHC staining | NA | 0.48 | 0.5461 | 24668028
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.48 | 0.5461 | 33068069
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 33995625
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 34400945
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.48 | 0.5461 | 33784109
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.5461 | 33670440
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 33437165
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 33468994
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34209829
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34277782
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34832951
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 35044041
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29017078
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | qPCR | NA | 0.48 | 0.5461 | 26181204
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 24646078
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.48 | 0.5461 | 26468775
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed +Cisplatin | RT-PCR | NA | 0.48 | 0.5461 | 26895954
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.48 | 0.5461 | 31201845
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5461 | 25003810
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5461 | 29225473
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5461 | 31368411
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.48 | 0.5461 | 26675547
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.48 | 0.5461 | 31796785
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 22900142
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | 5-Fluorouracil | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 25683371
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 25683371
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 27766570
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 28035349
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29138851
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29448000
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31024010
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32033067
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32401390
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32612672
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32655321
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 23370278
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 26546046
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 27009878
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 28787001
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 31582014
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31871777
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.5461 | 23009336
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.5461 | 22615765
|
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.5461 | 22825470
|
| NOTCH1 | 7881 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0477 | 30555330
|
| NOTCH1 | 7881 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0477 | 31939436
|
| NOTCH1 | 7881 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0477 | 22615765
|
| NOTCH1 | 7881 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | SFA followed by Western Blotting | NA | 0.48 | 0.0477 | 32726929
|
| PAX6 | 8620 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting and RT-PCR followed by SFA and Migration Invasion assay | NA | 0.48 | 0.0021 | 31024010
|
| PHC3 | 15682 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0021 | 34424425
|
| SHH | 10848 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0201 | 34424425
|
| SHH | 10848 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0201 | 30555330
|
| SHH | 10848 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0201 | 29262597
|
| SIRPG | 15757 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 35229723
|
| SMO | 11119 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0212 | 34424425
|
| SMO | 11119 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.0212 | 29225473
|
| SOX5 | 11201 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA and Migration Invasion assay | NA | 0.48 | 0.0011 | 29888108
|
| TGIF2 | 15764 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and Western Blotting followed by qRT-PCR and SFA | NA | 0.48 | 0.0021 | 31871777
|
| WNT1 | 12774 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0074 | 22615765
|
| WNT1 | 12774 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.48 | 0.0074 | 31819528
|
| WNT2 | 12780 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 22615765
|
| YAP1 | 16262 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0117 | 30128013
|
| YAP1 | 16262 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.0117 | 27911857
|
| FOXF1 | 3809 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and IF staining followed by SFA and Tumorigenicity assay | NA | 0.44 | 0.0032 | 32319573
|
| CACNA2D1 | 1399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.4 | 0.0064 | 25881239
|
| CACNA2D1 | 1399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.4 | 0.0064 | 25881239
|
| CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0498 | 34059086
|
| CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0498 | 34059086
|
| CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0498 | 34059086
|
| MYH9 | 7579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0064 | 34059086
|
| MYH9 | 7579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0064 | 25881239
|
| CACNA2D1 | 1399 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Tumorigenicity assay and SFA and Western Blotting | NA | 0.4 | 0.0064 | 33707423
|
| CACNA2D1 | 1399 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by qPCR and SFA | NA | 0.4 | 0.0064 | 30464601
|
| CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.0498 | 22370645
|
| CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and Western Blotting | NA | 0.4 | 0.0498 | 26779808
|
| CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.4 | 0.0498 | 33068069
|
| CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and CFA | NA | 0.4 | 0.0498 | 32329414
|
| MYH9 | 7579 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.0064 | 34635641
|
| RASSF1 | 9882 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.0021 | 25007054
|
| NCAM1 | 7656 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.36 | 0.0074 | 29416721
|
| NCAM1 | 7656 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.36 | 0.0074 | 29416721
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining followed by SFA and FACs | NA | 0.36 | 0.0583 | 31024010
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.36 | 0.0583 | 23947765
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.36 | 0.0583 | 31582014
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.36 | 0.0583 | 33068069
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.0583 | 33995625
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.36 | 0.0583 | 33670440
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.36 | 0.0583 | 33707423
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs | NA | 0.36 | 0.0583 | 33631674
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Curcumin+Cisplatin | FACs followed by SFA | NA | 0.36 | 0.0583 | 26531053
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.36 | 0.0583 | 29868483
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.36 | 0.0583 | 32655321
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.36 | 0.0583 | 25881239
|
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.36 | 0.0583 | 29187584
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by SFA and ICC staining | NA | 0.36 | 0.456 | 31939436
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA and FACs | NA | 0.36 | 0.456 | 25003810
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ICC staining | NA | 0.36 | 0.456 | 31582014
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.36 | 0.456 | 24961511
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.36 | 0.456 | 24961511
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and FACs followed by SFA and Tumorigenicity assay | NA | 0.36 | 0.456 | 29017078
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.456 | 26278043
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.456 | 26278043
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.456 | 28789457
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by Tumorigenicity assay | NA | 0.36 | 0.456 | 31796785
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 30555330
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs | NA | 0.36 | 0.456 | 22825470
|
| NCAM1 | 7656 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining | NA | 0.36 | 0.0074 | 34527268
|
| NCAM1 | 7656 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.0074 | 32466428
|
| ALDH1A2 | 15472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.32 | 0.0117 | 25881239
|
| EXO1 | 3511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Transcriptomics followed by Western Blotting | Up | 0.32 | 0.0042 | 24440048
|
| EXO1 | 3511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.32 | 0.0042 | 25881239
|
| MSH2 | 7325 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Transcriptomics followed by Western Blotting | Up | 0.32 | 0.0021 | 24440048
|
| RAD51 | 9817 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Transcriptomics followed by Western Blotting | Up | 0.32 | 0.0032 | 24440048
|
| XRCC6 | 4055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Transcriptomics followed by Western Blotting | Up | 0.32 | 0.0053 | 24440048
|
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR | NA | 0.32 | 0.0604 | 34400945
|
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.0604 | 33980809
|
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.0604 | 22900142
|
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.32 | 0.0604 | 22615765
|
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.32 | 0.0604 | 22855139
|
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SP assay and Tumorigenicity assay | NA | 0.32 | 0.0604 | 26940223
|
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.32 | 0.0604 | 26081992
|
| ALDH1A2 | 15472 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.32 | 0.0117 | 29262597
|
| ALDH1A2 | 15472 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | ALDEFLUOR assay | NA | 0.32 | 0.0117 | 26181204
|
| MIR5100 | 43540 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by FACs and SFA | NA | 0.32 | 0.0011 | 29144562
|
| NES | 7756 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by FACs and qRT-PCR | NA | 0.32 | 0.0573 | 29860718
|
| NRP1 | 8004 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and SFA followed by qRT-PCR | NA | 0.32 | 0.0053 | 29138851
|
| ABCC1 | 51 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0212 | 25881239
|
| CCND1 | 1582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0201 | 34059086
|
| CLOCK | 2082 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0021 | 25881239
|
| CLOCK | 2082 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0021 | 25881239
|
| COL17A1 | 2194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.28 | 0.0064 | 29416721
|
| COL17A1 | 2194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0064 | 25881239
|
| COL17A1 | 2194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0064 | 25881239
|
| CTNNB1 | 2514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0647 | 34059086
|
| CTNNB1 | 2514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0647 | 25881239
|
| GSTP1 | 4638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0053 | 34059086
|
| GSTP1 | 4638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0053 | 34059086
|
| NOTCH2 | 7882 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0117 | 34059086
|
| TGFB1 | 11766 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.28 | 0.0138 | 25432175
|
| TGFB1 | 11766 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0138 | 34059086
|
| TM4SF4 | 11856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0032 | 25881239
|
| TM4SF4 | 11856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0032 | 25881239
|
| TSPYL5 | 29367 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0032 | 25881239
|
| USP4 | 12627 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0021 | 25881239
|
| USP4 | 12627 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0021 | 25881239
|
| ABCC1 | 51 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 33980809
|
| ABCC1 | 51 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0212 | 25683371
|
| BACH1 | 935 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0011 | 34949193
|
| CAMK2G | 1463 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.28 | 0.0021 | 25965829
|
| CCND1 | 1582 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 33980809
|
| CDK1 | 1722 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0011 | 33721187
|
| CLOCK | 2082 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 33125096
|
| COL17A1 | 2194 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0064 | 31928533
|
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 33980809
|
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 24013232
|
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 27836540
|
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.28 | 0.0647 | 31819528
|
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting followed by Migration assay | NA | 0.28 | 0.0647 | 20074550
|
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.28 | 0.0647 | 34246759
|
| GSTP1 | 4638 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 34840986
|
| ITGB1 | 6153 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and Western Blotting followed by Tumorigenicity assay | NA | 0.28 | 0.018 | 30485693
|
| KCNK3 | 6278 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA and Migration assay | NA | 0.28 | 0.0021 | 29387193
|
| LGR5 | 4504 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.28 | 0.0753 | 32637578
|
| LGR5 | 4504 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.28 | 0.0753 | 34246759
|
| LGR5 | 4504 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.28 | 0.0753 | 31796785
|
| MSI1 | 7330 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 22370645
|
| MSI1 | 7330 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 23715514
|
| NOTCH2 | 7882 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0117 | 24013232
|
| NOTCH2 | 7882 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.28 | 0.0117 | 29254164
|
| RXRA | 10477 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0021 | 30058740
|
| SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.28 | 0.0212 | 34163000
|
| SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 35267489
|
| SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.28 | 0.0212 | 34400945
|
| SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0212 | 32033067
|
| TGFB1 | 11766 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA and Migration Invasion assay | NA | 0.28 | 0.0138 | 32606331
|
| TGFB1 | 11766 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Migration and Invasion assay | NA | 0.28 | 0.0138 | 28789457
|
| TM4SF4 | 11856 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA and Migration Invasion assay | NA | 0.28 | 0.0032 | 29254164
|
| TSPYL5 | 29367 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.28 | 0.0032 | 34163000
|
| UBE3C | 16803 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting and SFA followed by Migration and Invasion assay | NA | 0.28 | 0.0021 | 30503554
|
| USP4 | 12627 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0021 | 32549341
|
| VIM | 12692 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.28 | 0.017 | 34163000
|
| VIM | 12692 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.017 | 35267489
|
| YBX1 | 8014 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by Invasion assay and SFA | NA | 0.28 | 0.0021 | 28400280
|
| AKR1C1 | 384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.24 | 0.0085 | 33670440
|
| AKR1C1 | 384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0085 | 25881239
|
| AKR1C2 | 385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.24 | 0.0053 | 33670440
|
| AKR1C2 | 385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0053 | 25881239
|
| BMP6 | 1073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
| BMP6 | 1073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0021 | 25881239
|
| CCL2 | 10618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0074 | 25432175
|
| CCL2 | 10618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0074 | 34059086
|
| CCL2 | 10618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0074 | 25881239
|
| CCL5 | 10632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0064 | 25432175
|
| CCL5 | 10632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0064 | 35229723
|
| CRLF1 | 2364 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 25432175
|
| CSF2 | 2434 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
| CSF3 | 2438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25432175
|
| CYR61 | 2654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 25432175
|
| CYR61 | 2654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0053 | 34059086
|
| CYR61 | 2654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0053 | 25881239
|
| CYR61 | 2654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0053 | 25881239
|
| EDIL3 | 3173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
| GAL | 4114 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25432175
|
| IL11 | 5966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25432175
|
| IL8 | 6025 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0159 | 25432175
|
| IL8 | 6025 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0159 | 25881239
|
| INHA | 6065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25432175
|
| INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25432175
|
| INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25432175
|
| INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 25881239
|
| INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 25881239
|
| INHBB | 6067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0064 | 25432175
|
| INHBC | 6068 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 25432175
|
| INHBE | 24029 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
| MIR210 | 31587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0064 | 22301433
|
| MIR26B | 31612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0032 | 22301433
|
| MIR26B | 31612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0032 | 33959615
|
| MIR26B | 31612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0032 | 33959615
|
| MIR31 | 31630 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0064 | 22301433
|
| MIR497 | 32088 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0053 | 31692042
|
| MIRLET7C | 31480 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0042 | 22301433
|
| MIRLET7E | 31482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0032 | 22301433
|
| NODAL | 7865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 25432175
|
| PDGFA | 8799 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
| PDGFA | 8799 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0021 | 25881239
|
| PDGFB | 8800 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25432175
|
| PTHLH | 9607 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25432175
|
| PTHLH | 9607 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 25881239
|
| PTHLH | 9607 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 25881239
|
| TGFB2 | 11768 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0074 | 25432175
|
| TGFB3 | 11769 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
| AKR1C1 | 384 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0085 | 18034892
|
| AKR1C2 | 385 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 18034892
|
| MIR130B | 31515 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 28534939
|
| MIR181B1 | 31550 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 28534939
|
| MIR25 | 31609 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 28534939
|
| MIR302A | 31623 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 28534939
|
| MIR302C | 31764 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 28534939
|
| MIR497 | 32088 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 28534939
|
| MIR671 | 33134 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 28534939
|
| MIRLET7E | 31482 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 28534939
|
| ATXN1 | 10548 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.24 | 0.0064 | 21520032
|
| ATXN1 | 10548 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.24 | 0.0064 | 26261505
|
| MIR31 | 31630 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.24 | 0.0064 | 34277782
|
| MIRLET7C | 31480 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.24 | 0.0042 | 34277782
|
| CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 35229723
|
| CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 29416721
|
| CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 29416721
|
| CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 29416721
|
| CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 29416721
|
| MIR30A | 31624 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0085 | 31692042
|
| MIR30A | 31624 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0085 | 31692042
|
| MIR582 | 32838 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.2 | 0.0064 | 22301433
|
| MIRLET7F1 | 31483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0053 | 31692042
|
| MIRLET7G | 31485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.2 | 0.0032 | 22301433
|
| ZEB1 | 11642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0074 | 25881239
|
| ZEB1 | 11642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0074 | 25881239
|
| ABCA2 | 32 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by invasion assay and RT-PCR | NA | 0.2 | 0.0021 | 17510412
|
| CD34 | 1662 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 30981768
|
| CD34 | 1662 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0053 | 21520032
|
| CD34 | 1662 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by FACs | NA | 0.2 | 0.0053 | 22370645
|
| CEACAM1 | 1814 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.0064 | 22855139
|
| DNMT1 | 2976 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 29044153
|
| KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.018 | 21520032
|
| KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.2 | 0.018 | 20028869
|
| KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.2 | 0.018 | 20028869
|
| MACsC1-AS1 | 41257 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 32401390
|
| MIR145 | 31532 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0032 | 34277782
|
| MIR181C | 31552 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0032 | 34277782
|
| MIR196B | 31790 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.2 | 0.0021 | 34277782
|
| MIR212 | 31589 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.2 | 0.0021 | 34277782
|
| MIR30A | 31624 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0085 | 34277782
|
| MIR410 | 32065 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.2 | 0.0011 | 28076327
|
| MIR490 | 32075 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0011 | 34277782
|
| MIR582 | 32838 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.2 | 0.0064 | 34277782
|
| MIR582 | 32838 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Tumorigenicity assay followed by SFA | NA | 0.2 | 0.0064 | 26468775
|
| MIR873 | 33663 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.2 | 0.0021 | 34277782
|
| MIR99A | 31650 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0021 | 34277782
|
| MIRLET7F1 | 31483 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0053 | 34277782
|
| MIRLET7G | 31485 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0032 | 34277782
|
| SLC7A5 | 11063 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0042 | 34681614
|
| TMPRSS4 | 11878 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Migration Invasion assay | NA | 0.2 | 0.0042 | 26546046
|
| TWIST2 | 20670 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.2 | 0.0011 | 33468994
|
| ZEB1 | 11642 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.2 | 0.0074 | 33468994
|
| ZNF322 | 23640 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 30258097
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.12 | 0.456 | 34277782
|
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Tumorigenicity assay | NA | 0.12 | 0.456 | 33707423
|
| DRD2 | 3023 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.12 | 0.0011 | 27920206
|
| TRPM7 | 17994 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by SFA and FACs | NA | 0.12 | 0.0021 | 30477473
|
| ACTB | 132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
| ACTN4 | 166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0074 | 33670440
|
| AHSG | 349 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 33670440
|
| AKR1B10 | 382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
| AKR1B10 | 382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
| AKR1B10 | 382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
| AKR1C3 | 386 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
| AKR1C3 | 386 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
| AKR1C3 | 386 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
| AKR1C4 | 387 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
| ALDOA | 414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
| ANXA1 | 533 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
| ANXA1 | 533 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
| CLU | 2095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0064 | 33670440
|
| CLU | 2095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0064 | 33670440
|
| CLU | 2095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0064 | 25881239
|
| CLU | 2095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0064 | 25881239
|
| CST3 | 2475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 33670440
|
| ENO1 | 3350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0095 | 33670440
|
| FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
| FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.08 | 0.0053 | 29416721
|
| FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.08 | 0.0053 | 29416721
|
| FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.08 | 0.0053 | 29416721
|
| FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.08 | 0.0053 | 29416721
|
| GAPDH | 4141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
| GAS2L1 | 16955 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
| IGFBP4 | 5473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
| IGFBP4 | 5473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
| IGFBP4 | 5473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
| IGFBP4 | 5473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
| KRT8 | 6446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0074 | 33670440
|
| KRT8 | 6446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0074 | 33670440
|
| KRT8 | 6446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0074 | 25881239
|
| KRT8 | 6446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0074 | 25881239
|
| PFN1 | 8881 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
| PRSS1 | 9475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 33670440
|
| PRSS1 | 9475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0032 | 25881239
|
| PRSS1 | 9475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0032 | 25881239
|
| PRSS3 | 9486 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
| PRSS3 | 9486 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0021 | 25881239
|
| PRSS3 | 9486 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0021 | 25881239
|
| PRSS3 | 9486 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0021 | 25881239
|
| S100A6 | 10496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
| TMSB10 | 11879 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 33670440
|
| TMSB4X | 11881 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
| TNP1 | 11951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 33670440
|
| YWHAB | 12849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 33670440
|
| YWHAB | 12849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0032 | 34059086
|
| YWHAQ | 12854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 33670440
|
| YWHAZ | 12855 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
| A1CF | 24086 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| AAGAB | 25662 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| AAMP | 18 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| AARS1 | 20 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| AASS | 17366 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AASS | 17366 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AATK | 21 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ABCA12 | 14637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29316740
|
| ABCA12 | 14637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ABCA12 | 14637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ABCC10 | 52 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ABCC2 | 53 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 25881239
|
| ABCC2 | 53 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 25881239
|
| ABCC2 | 53 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Gene ChIP analysis | Up | 0.04 | 0.0106 | 18423378
|
| ABCC3 | 54 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ABCC3 | 54 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ABCC4 | 55 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ABCC4 | 55 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ABCG1 | 73 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
| ABCG1 | 73 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ABHD4 | 20154 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ABHD5 | 21396 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ABRACL | 21230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ABTB2 | 23842 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ACADSB | 91 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ACADSB | 91 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ACAT2 | 94 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ACAT2 | 94 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ACBD5 | 23338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ACCS | 23989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ACO2 | 118 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| ACOT2 | 18431 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29316740
|
| ACOT2 | 18431 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ACP1 | 122 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ACP6 | 29609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ACSL4 | 3571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ACSL4 | 3571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ACSM3 | 10522 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ACSM3 | 10522 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ACSS1 | 16091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ACSS1 | 16091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ACSS1 | 16091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ACTN1 | 163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ACTN1 | 163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ADAM12 | 190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| ADAM23 | 202 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ADAM23 | 202 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ADAM28 | 206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ADAM28 | 206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ADAMTS1 | 217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ADAMTS1 | 217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ADAMTS13 | 1366 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ADAMTS6 | 222 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ADAMTS6 | 222 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ADCY1 | 232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ADCY3 | 234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ADCY7 | 238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ADGRA3 | 13839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ADGRE2 | 3337 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
| ADGRG2 | 4516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ADGRG2 | 4516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ADGRG6 | 13841 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ADGRL4 | 20822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ADGRV1 | 17416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| ADH6 | 255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ADK | 257 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ADK | 257 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ADM | 259 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ADORA2B | 264 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ADORA2B | 264 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ADRA1B | 278 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| AFDN | 7137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AFDN | 7137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AFMID | 20910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AGMAT | 18407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AGO2 | 3263 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AGO2 | 3263 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AGR2 | 328 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| AGT | 333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| AHI1-DT | 32526 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AHNAK | 347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| AHSA1 | 1189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AHSA1 | 1189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AIFM1 | 8768 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| AIG1 | 21607 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AK4 | 363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AK4 | 363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AK7 | 20091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| AKAP12 | 370 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| AKAP13 | 371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| AKR1B1 | 381 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| AKR1B1 | 381 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| AKR1E2 | 23437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| AKR7A2 | 389 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AKT3 | 393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| AKT3 | 393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ALDH3A1 | 405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 35229723
|
| ALDH3A1 | 405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
| ALDOC | 418 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ALDOC | 418 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ALG1 | 18294 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ALG8 | 23161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ALKBH2 | 32487 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ALKBH2 | 32487 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ALPK2 | 20565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ALPK2 | 20565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ALX1 | 1494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ALX1 | 1494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| AMDHD1 | 28577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| AMIGO1 | 20824 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AMIGO2 | 24073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| AMN1 | 27281 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| AMOTL1 | 17811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AMOTL1 | 17811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| AMZ2P1 | 26491 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ANG | 483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ANG | 483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ANGPT1 | 484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| ANK3 | 494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ANKRD1 | 15819 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ANKRD1 | 15819 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ANKRD20A11P | 42024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ANKRD20A12P | 43603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ANKRD20A2P | 31979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ANKRD20A8P | 23666 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ANKRD20A8P | 23666 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ANKRD22 | 28321 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ANKRD50 | 29223 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ANKRD50 | 29223 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ANKRD52 | 26614 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ANKS4B | 26795 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
| ANKZF1 | 25527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ANKZF1 | 25527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ANKZF1 | 25527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ANO1 | 21625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ANO1 | 21625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ANO4 | 23837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ANO4 | 23837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ANO5 | 27337 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ANO5 | 27337 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ANO5 | 27337 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ANP32C | 16675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ANPEP | 500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 25881239
|
| ANTXR1 | 21014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ANTXR1 | 21014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ANTXR2 | 21732 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| ANTXR2 | 21732 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ANTXR2 | 21732 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ANXA13 | 536 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ANXA13 | 536 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ANXA3 | 541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 25881239
|
| ANXA3 | 541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 25881239
|
| ANXA4 | 542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ANXA4 | 542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ANXA8 | 546 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ANXA8L1 | 23334 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ANXA8L1 | 23334 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ANXA8L1 | 23334 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| AOX1 | 553 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| AOX1 | 553 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| AP3S2 | 571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| AP3S2 | 571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| AP5B1 | 25104 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AP5S1 | 15875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| APBB2 | 582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| APBB2 | 582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| APLP2 | 598 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| APOBEC3A | 17343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| APOBEC3B | 17352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| APOBEC3F | 17356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| APOD | 612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
| APOD | 612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| APOH | 616 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| APOH | 616 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| AR | 644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| AR | 644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ARAP2 | 16924 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
| AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| ARG2 | 664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
| ARG2 | 664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ARHGAP11A | 15783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ARHGAP12 | 16348 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ARHGAP23 | 29293 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ARHGAP26 | 17073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ARHGAP29 | 30207 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ARHGAP42 | 26545 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ARHGAP42 | 26545 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ARHGDIB | 679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ARHGDIB | 679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ARHGEF17 | 21726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ARHGEF17 | 21726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| ARHGEF18 | 17090 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ARHGEF35 | 33846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ARHGEF35 | 33846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ARHGEF39 | 25909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ARHGEF5 | 13209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ARHGEF5 | 13209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ARHGEF5 | 13209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ARHGEF5 | 13209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ARID3B | 14350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ARID4A | 9885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ARID5B | 17362 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ARL4C | 698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ARNTL2 | 18984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ARNTL2 | 18984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ARRB1 | 711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ARRB2 | 712 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ARRB2 | 712 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ARSD | 717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ARSJ | 26286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ARSJ | 26286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ARSL | 719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ARSL | 719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| AS3MT | 17452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ASAP2 | 2721 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ASAP2 | 2721 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ASB1 | 16011 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ASB4 | 16009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ASGR1 | 742 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ASGR1 | 742 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ASIC4 | 21263 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ASRGL1 | 16448 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| ATAD2B | 29230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ATF7IP2 | 20397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ATP10D | 13549 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ATP10D | 13549 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ATP11B | 13553 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ATP2B1 | 814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ATP2B1 | 814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ATP2B4 | 817 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ATP2B4 | 817 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ATP5G1 | 841 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ATP6V0D1 | 13724 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ATP7A | 869 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ATP7A | 869 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ATP8B1 | 3706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ATP9A | 13540 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ATRX | 886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ATRX | 886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ATRX | 886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ATXN8 | 32925 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AVEN | 13509 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| AVP | 894 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
| AVPI1 | 30898 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| AXIN1 | 903 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| B3GALNT1 | 918 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| B3GALNT1 | 918 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| B3GNT3 | 13528 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| B3GNT5 | 15684 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| B3GNT5 | 15684 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| B4GALNT1 | 4117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| B4GALT4 | 927 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| B4GALT4 | 927 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| B4GALT6 | 929 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| BAAT | 932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| BABAM2 | 1106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BACE2 | 934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| BAG2 | 938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BAG6 | 13919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| BAHCC1 | 29279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| BAMBI | 30251 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| BAMBI | 30251 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| BANF1 | 17397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| BARX2 | 956 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| BASP1 | 957 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| BAX | 959 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| BBS4 | 969 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BCAR3 | 973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| BCAR3 | 973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| BCAS1 | 974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| BCAS3 | 14347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| BCAT1 | 976 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| BCL10 | 989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| BCL2A1 | 991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| BCL2L15 | 33624 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| BCL2L15 | 33624 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| BCO1 | 13815 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BCO2 | 18503 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| BCOR | 20893 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| BCOR | 20893 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| BCR | 1014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| BCR | 1014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| BDNF | 1033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| BDNF | 1033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| BEND4 | 23815 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| BEND7 | 23514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BFAR | 17613 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| BICC1 | 19351 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| BICC1 | 19351 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| BIRC3 | 591 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| BIRC3 | 591 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| BIRC3 | 591 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| BIRC5 | 593 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| BLM | 1058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| BLM | 1058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| BLMH | 1059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| BLVRB | 1063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BMPR1B | 1077 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BMPR1B | 1077 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BNC1 | 1081 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| BNC1 | 1081 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| BNC2 | 30988 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| BORCS7-ASMT | 49183 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BRCA1 | 1100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| BRCA1 | 1100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| BRCA1 | 1100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| BRP44 | 24515 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| BRWD1 | 12760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| C11ORF86 | 34442 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| C12ORF48 | 26074 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| C14ORF2 | 1188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| C17ORF67 | 27900 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| C18ORF12 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| C18ORF54 | 13796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| C1ORF116 | 28667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| C1ORF116 | 28667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| C1ORF21 | 15494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| C1QL3 | 19359 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| C1S | 1247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| C1S | 1247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| C21ORF91 | 16459 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| C3ORF18 | 24837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| C4BPA | 1325 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| C5 | 1331 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| C5 | 1331 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| C8orf37 | 27232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| C8orf37 | 27232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| C9ORF92 | 19054 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CA12 | 1371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CA12 | 1371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CA13 | 14914 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CA13 | 14914 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CA2 | 1373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
| CA2 | 1373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CA2 | 1373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CA8 | 1382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CA8 | 1382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CAB39 | 20292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CAB39 | 20292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CABIN1 | 24187 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CABLES2 | 16143 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CACNA1B | 1389 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CACNA1D | 1391 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CACTIN | 29938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CAD | 1424 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CADM1 | 5951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CADM1 | 5951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CADM2 | 29849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CADM3 | 17601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CALCOCO2 | 29912 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CAMK1D | 19341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| CAMK2D | 1462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CAMK2D | 1462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CAP1 | 20040 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CAPN1 | 1476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CAPN5 | 1482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CAPNS2 | 16371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CAPRIN1 | 6743 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CARD6 | 16394 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CARD6 | 16394 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CARMN | 42872 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CASKIN1 | 20879 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CASP3 | 1504 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CASP4 | 1505 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CASP4 | 1505 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CASS4 | 15878 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CASTOR2 | 37073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CASTOR2 | 37073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CASTOR3 | 29954 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CAT | 1516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| CAT | 1516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| CATSPER1 | 17116 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CAV1 | 1527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 25881239
|
| CAV2 | 1528 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| CAV2 | 1528 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| CBFA2T3 | 1537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CBX2 | 1552 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CBX8 | 15962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CCBE1 | 29426 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CCBE1 | 29426 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CCDC144A | 29072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC144A | 29072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC144B | 26704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC144B | 26704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC144CP | 29073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC144CP | 29073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC198 | 20189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CCDC198 | 20189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CCDC22 | 28909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CCDC34 | 25079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC34 | 25079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC43 | 26472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CCDC57 | 27564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CCDC68 | 24350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC77 | 28203 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCDC78 | 14153 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CCDC80 | 30649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CCDC80 | 30649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CCDC85A | 29400 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CCDC88C | 19967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CCL20 | 10619 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 35229723
|
| CCL20 | 10619 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| CCNA1 | 1577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CCNA1 | 1577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CCNA2 | 1578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| CCNA2 | 1578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| CCNA2 | 1578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| CCNB1 | 1579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| CCND2 | 1583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CCND2 | 1583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CCND3 | 1585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCNE1 | 1589 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CCNG2 | 1593 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CCNG2 | 1593 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CCPG1 | 24227 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CCR8 | 1609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CCT6B | 1621 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CCT7 | 1622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CD22 | 1643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| CD22 | 1643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| CD274 | 17635 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CD274 | 17635 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CD302 | 30843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CD302 | 30843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CD302 | 30843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CD302 | 30843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CD36 | 1663 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| CD36 | 1663 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| CD47 | 1682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CD47 | 1682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CD55 | 2665 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CD58 | 1688 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| CD59 | 1689 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CD59 | 1689 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CD68 | 1693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CD74 | 1697 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CD84 | 1704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CD9 | 1709 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CD9 | 1709 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CD93 | 15855 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CD99L2 | 18237 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| CDC20 | 1723 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CDC20 | 1723 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CDC25A | 1725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CDC25B | 1726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CDC42EP3 | 16943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDC42EP3 | 16943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDCP1 | 24357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CDCP1 | 24357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CDH11 | 1750 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| CDH11 | 1750 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| CDH13 | 1753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CDH13 | 1753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CDH16 | 1755 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CDH17 | 1756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| CDH17 | 1756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CDH17 | 1756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CDH2 | 1759 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0085 | 25881239
|
| CDH23 | 13733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CDH3 | 1762 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDH3 | 1762 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDH6 | 1765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| CDH6 | 1765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| CDH6 | 1765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDH8 | 1767 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CDHR1 | 14550 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CDK11A | 1730 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CDK12 | 24224 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CDK14 | 8883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CDK14 | 8883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CDK17 | 8750 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CDK19 | 19338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDK2 | 1771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CDK6 | 1777 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CDKL5 | 11411 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDKN1A | 1784 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| CDKN2B-AS1 | 34341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDKN2B-AS1 | 34341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDKN3 | 1791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDKN3 | 1791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDR1 | 1798 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDR1 | 1798 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDRT1 | 14379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDRT1 | 14379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDRT1 | 14379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDRT1 | 14379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CDS1 | 1800 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDS1 | 1800 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CDT1 | 24576 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CEACAM6 | 1818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
| CEACAM6 | 1818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| CEBPB | 1834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CENPA | 1851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| CENPE | 1856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CENPE | 1856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CENPE | 1856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CENPO | 28152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CENPV | 29920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CENPV | 29920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CEP112 | 28514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CEP112 | 28514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CEP126 | 29264 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CES1 | 1863 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CES1 | 1863 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CFAP20DC | 24763 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CFAP20DC | 24763 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CFAP251 | 28506 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CFAP251 | 28506 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CFL2 | 1875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| CHAF1B | 1911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CHD4 | 1919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CHD9 | 25701 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CHERP | 16930 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CHGB | 1930 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CHID1 | 28474 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CHML | 1941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CHMP1A | 8740 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CHN1 | 1943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CHN1 | 1943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CHORDC1 | 14525 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CHPT1 | 17852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CHPT1 | 17852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CHRNA5 | 1959 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CHRNA5 | 1959 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CHRNB1 | 1961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CHRNB1 | 1961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CHST12 | 17423 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CHSY1 | 17198 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CHTF18 | 18435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CIAO3 | 14179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CIDEC | 24229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CIT | 1985 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CKMT1A | 31736 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CKMT1A | 31736 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CKMT1B | 1995 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CKMT1B | 1995 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CLCA2 | 2016 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CLCA2 | 2016 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CLCC1 | 29675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CLCC1 | 29675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CLDN1 | 2032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| CLDN10 | 2033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CLDN10 | 2033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| CLDN11 | 8514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CLDN11 | 8514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CLDN12 | 2034 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CLDN18 | 2039 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CLDN2 | 2041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CLDN2 | 2041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| CLDN7 | 2049 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| CLEC4E | 14555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CLIC1 | 2062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| CLIC1 | 2062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| CLIC1 | 2062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| CLIC1 | 2062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| CLMN | 19972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CLMN | 19972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CLMP | 24039 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CLMP | 24039 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CLN6 | 2077 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CLSPN | 19715 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CLSTN1 | 17447 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CLSTN1 | 17447 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CLTB | 2091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CMTM7 | 19178 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CMTM8 | 19179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CNKSR2 | 19701 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CNKSR2 | 19701 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CNN2 | 2156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CNN2 | 2156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CNNM1 | 102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CNNM1 | 102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CNNM2 | 103 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CNNM4 | 105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CNNM4 | 105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CNNM4 | 105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CNTLN | 23432 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CNTN1 | 2171 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CNTN1 | 2171 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CNTNAP2 | 13830 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CNTNAP3B | 32035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CNTNAP3B | 32035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CNTNAP4 | 18747 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| COA3 | 24990 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| COBLL1 | 23571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| COCH | 2180 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| COCH | 2180 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| COG7 | 18622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| COL12A1 | 2188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| COL12A1 | 2188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| COL12A1 | 2188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| COL13A1 | 2190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| COL14A1 | 2191 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| COL16A1 | 2193 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| COL28A1 | 22442 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| COL4A3 | 2204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| COL5A2 | 2210 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| COL6A1 | 2211 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| COL7A1 | 2214 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| COL7A1 | 2214 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| COMMD10 | 30201 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| COPS7A | 16758 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| COQ4 | 19693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CORO1B | 2253 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CORO2A | 2255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CORO2A | 2255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CORO2A | 2255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| COX6B1 | 2280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| COX7B | 2291 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CP | 2295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CP | 2295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CPA4 | 15740 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| CPE | 2303 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| CPEB1 | 21744 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CPEB4 | 21747 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CPLX2 | 2310 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CPLX2 | 2310 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CPNE4 | 2317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CPNE4 | 2317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CPOX | 2321 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CPPED1 | 25632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CPPED1 | 25632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CPPED1 | 25632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CPS1 | 2323 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| CPS1 | 2323 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| CPXM2 | 26977 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| CRABP1 | 2338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CRABP2 | 2339 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CREB5 | 16844 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CREBL2 | 2350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CREBRF | 24050 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CRH | 2355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CRIP1 | 2360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CRIPT | 14312 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CROCCP2 | 28170 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CROT | 2366 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CRYBG1 | 356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CRYBG1 | 356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CRYBG2 | 17295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CRYZ | 2419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CRYZ | 2419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CSAG1 | 24294 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CSGALNACT1 | 24290 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| CSGALNACT1 | 24290 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| CSNK1E | 2453 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CSNK1E | 2453 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CST1 | 2473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| CSTA | 2481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CSTA | 2481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| CTAGE15 | 2481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE15 | 2481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE4 | 24772 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE4 | 24772 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE6 | 28644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE6 | 28644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE8 | 37294 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE8 | 37294 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE9 | 37275 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTAGE9 | 37275 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTNNAL1 | 2512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| CTSB | 2527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| CTSF | 2531 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| CTSK | 2536 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CTSL | 2537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CTSL | 2537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CTTNBP2NL | 25330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CTTNBP2NL | 25330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CUTC | 24271 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CXADR | 2559 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CXADR | 2559 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CXCL1 | 4602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| CXCL1 | 4602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| CXCL2 | 4603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| CYB561 | 2571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CYB5A | 2570 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CYB5R1 | 13397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CYB5R2 | 24376 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CYB5R2 | 24376 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| CYBRD1 | 20797 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CYBRD1 | 20797 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CYFIP2 | 13760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CYFIP2 | 13760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| CYP1B1 | 2597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 29416721
|
| CYP1B1 | 2597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| CYP24A1 | 2602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CYP24A1 | 2602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CYP3A5 | 2638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CYP3A7 | 2640 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| CYP4F11 | 13265 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CYP4F11 | 13265 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| CYP4F2 | 2645 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| CYP4F3 | 2646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| DAAM1 | 18142 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DAPK1 | 2674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| DAPK1 | 2674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| DAPP1 | 16500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| DAPP1 | 16500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| DBF4B | 17883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DCAF11 | 20258 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DCAF11 | 20258 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DCAF12 | 19911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DCAF6 | 30002 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DCDC2 | 18141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DCDC2 | 18141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DCLRE1A | 17660 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DDB2 | 2718 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29316740
|
| DDC | 2719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DDX23 | 17347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DDX55 | 20085 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DDX58 | 19102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DDX58 | 19102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DENND11 | 29472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| DENND2B | 11350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DENND5B | 28338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DENND5B | 28338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DET1 | 25477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DET1 | 25477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DEXI | 13267 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DGAT1 | 2843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DGCR5 | 16757 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DGKA | 2849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DGKA | 2849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DGKD | 2851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DGKD | 2851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DGKH | 2854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DGKH | 2854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DHCR24 | 2859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| DHCR24 | 2859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| DHCR24 | 2859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| DHCR7 | 2860 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| DHFR | 2861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| DHFR | 2861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| DHFR | 2861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| DHRS1 | 16445 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DHRS1 | 16445 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DHRS9 | 16888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
| DHX38 | 17211 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| DHX40 | 18018 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DHX40 | 18018 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DICER1-AS1 | 43017 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DIO3OS | 20348 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DIS3L | 28698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DIS3L | 28698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DIXDC1 | 23695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DKK3 | 2893 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| DKK3 | 2893 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| DLG1 | 2900 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DLG1 | 2900 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DLGAP1-AS1 | 31676 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DLX4 | 2917 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DMAC2 | 25496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DMKN | 25063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| DMKN | 25063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| DMRTC1 | 13910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DMXL2 | 2938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DMXL2 | 2938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DNA2 | 2939 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DNAAF11 | 16725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DNAJC12 | 28908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| DNAJC12 | 28908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| DNAJC22 | 25802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DNAJC3 | 9439 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DNAJC5 | 16235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DND1 | 23799 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DNM1 | 2972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DNM1 | 2972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DOCK10 | 23479 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| DOCK11 | 23483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DOCK4 | 19192 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DOCK4 | 19192 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DOCK7 | 19190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DOCK7 | 19190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DOCK8 | 19191 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| DOCK9 | 14132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DOCK9 | 14132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DOK4 | 19868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DOK4 | 19868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DOLK | 23406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DOLK | 23406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DOP1B | 1291 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DOP1B | 1291 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DPP4 | 3009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0085 | 29416721
|
| DPP9 | 18648 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DPY19L1 | 22205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DPY19L1 | 22205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DPYSL2 | 3014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| DPYSL2 | 3014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| DPYSL3 | 3015 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DRAP1 | 3019 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DSC2 | 3036 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 29416721
|
| DSC2 | 3036 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| DSC2 | 3036 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| DSC3 | 3037 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DSC3 | 3037 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DSE | 21144 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DSE | 21144 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DSEL | 18144 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DSG2 | 3049 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| DSG3 | 3050 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| DSG3 | 3050 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| DSG3 | 3050 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| DSP | 3052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| DSTNP2 | 34546 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DTX2 | 15973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DUS2 | 26014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DUSP1 | 3064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| DUSP1 | 3064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| DUSP16 | 17909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| DUSP28 | 33237 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DUSP6 | 3072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| DUSP6 | 3072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| DUSP7 | 3073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DUSP7 | 3073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| DUXAP9 | 32188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DUXAP9 | 32188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| DYNLL2 | 24596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| DZIP1 | 20908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| DZIP3 | 30938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| DZIP3 | 30938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| E2F1 | 3113 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| E2F5 | 3119 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| E2F5 | 3119 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| E2F7 | 23820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29316740
|
| E2F7 | 23820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| E2F7 | 23820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| E2F8 | 24727 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EAPP | 19312 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EBF1 | 3126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EBF1 | 3126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EBP | 3133 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ECH1 | 3149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ECH1 | 3149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| EDA | 3157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| EDA | 3157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| EDA2R | 17756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EDEM1 | 18967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EDEM1 | 18967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EDN1 | 3176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| EDN1 | 3176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| EDN2 | 3177 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| EDNRA | 3179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EDNRA | 3179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EFEMP1 | 3218 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| EFEMP1 | 3218 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| EFNA1 | 3221 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| EFNA1 | 3221 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| EFNA1 | 3221 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| EFNB2 | 3227 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EFNB2 | 3227 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EFTUD2 | 30858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EGFR | 3236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| EGFR | 3236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| EGR1 | 3238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| EHBP1 | 29144 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| EHD1 | 3242 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| EHD4 | 3245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EHF | 3246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| EHF | 3246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| EID3 | 32961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| EIF2AK4 | 19687 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EIF2AK4 | 19687 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ELAPOR1 | 29618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ELAPOR2 | 21945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ELAPOR2 | 21945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ELAVL2 | 3313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ELK3 | 3325 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ELL2 | 17064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ELL2 | 17064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ELL2 | 17064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ELL2 | 17064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ELMO1 | 16286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ELMO1 | 16286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ELOA | 11620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ELOVL1 | 14418 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ELOVL2 | 14416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| ELOVL2 | 14416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ELOVL2 | 14416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ELOVL6 | 15829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ELOVL6 | 15829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| EMB | 30465 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EMB | 30465 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EME1 | 24965 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| EML1 | 3330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| EML1 | 3330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| EML4 | 1316 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| EML4 | 1316 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| EMP1 | 3333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| EMP1 | 3333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| EMX1 | 3340 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ENDOD1 | 29129 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ENDOV | 26640 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ENGASE | 24622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ENO2 | 3353 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| ENPP1 | 3356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ENPP1 | 3356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ENPP5 | 13717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ENTPD1 | 3363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| ENTPD3 | 3365 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ENTPD3 | 3365 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| EOGT | 28526 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EOGT | 28526 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EPB41L1 | 3378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| EPB41L1 | 3378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| EPB41L4A-DT | 25643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| EPDR1 | 17572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| EPHA7 | 3390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EPHB3 | 3394 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
| EPHB3 | 3394 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
| EPHX1 | 3401 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| EPHX1 | 3401 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| EPS8 | 3420 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| EPS8L2 | 21296 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ERAP1 | 18173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ERAP2 | 29499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ERAP2 | 29499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ERBB2 | 3430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
| ERBB2 | 3430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
| ERC2-IT1 | 1229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ERCC6 | 3438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ERCC6 | 3438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ERI2 | 30541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ERICH1 | 27234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ERLEC1 | 25222 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ERO1A | 13280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ERO1B | 14355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ESCO2 | 27230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ESCO2 | 27230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ESRP1 | 25966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ESRP1 | 25966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ESRP2 | 26152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ESYT1 | 29534 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ETFB | 3482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ETFB | 3482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ETFBKMT | 28739 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ETFBKMT | 28739 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ETHE1 | 23287 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ETNK1 | 24649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ETNK1 | 24649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ETS1 | 3488 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ETS1 | 3488 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ETS2 | 3489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ETV1 | 3490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ETV1 | 3490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| EVA1C | 13239 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| EWSR1 | 3508 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| EWSR1 | 3508 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| EXOC6 | 23196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EXOC6 | 23196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| EXOSC4 | 18189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| EXT1 | 3512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| EXTL3 | 3518 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EYA1 | 3519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EYA1 | 3519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| EYA3 | 3521 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| F11R | 14685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| F11R | 14685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| F11R | 14685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| F2 | 3535 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| F2R | 3537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| F2RL1 | 3538 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| F2RL1 | 3538 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| F2RL2 | 3539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| F2RL2 | 3539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| F3 | 3541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| F3 | 3541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| F5 | 3542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
| F5 | 3542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| F5 | 3542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| F5 | 3542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| F8A1 | 3547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| F8A1 | 3547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| F8A1 | 3547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| F8A2 | 31849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| F8A2 | 31849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| F8A3 | 31850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| F8A3 | 31850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FAHD1 | 14169 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FAM102B | 27637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| FAM102B | 27637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| FAM107B | 23726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FAM107B | 23726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FAM117B | 14440 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FAM126A | 24587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FAM136A | 25911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FAM160A1 | 34237 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FAM160A1 | 34237 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FAM161A | 25808 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FAM171B | 29412 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FAM171B | 29412 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FAM172BP | 34336 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FAM3A | 13749 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FAM3C | 18664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FAM3C | 18664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FAM3C | 18664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FAM3C | 18664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FAM81A | 28379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FAM83A | 28210 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FAM83A | 28210 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FAM83B | 21357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FAM83B | 21357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FAM83H | 24797 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FAM86B1 | 28268 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FAM86B1 | 28268 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FAM86B1 | 28268 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FAM86C1P | 25561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FAN1 | 29170 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FANCB | 3583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FANCF | 3587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FAR2 | 25531 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FAR2 | 25531 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FAS | 11920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FAS | 11920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FAT2 | 3596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FAT2 | 3596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FAT3 | 23112 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| FAT3 | 23112 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| FAT4 | 23109 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FBLN5 | 3602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FBN2 | 3604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FBXL18 | 21874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FBXL20 | 24679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FBXL20 | 24679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FBXO17 | 18754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FBXO17 | 18754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FBXO2 | 13581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| FBXO41 | 29409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FBXW7 | 16712 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FCGBP | 13572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 35229723
|
| FCGBP | 13572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FCSK | 29500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FDFT1 | 3629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FDFT1 | 3629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FDPS | 3631 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FERMT1 | 15889 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| FERMT1 | 15889 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FERMT1 | 15889 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FERMT2 | 15767 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FES | 3657 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FEZ1 | 3659 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FEZ1 | 3659 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FGA | 3661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FGA | 3661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FGB | 3662 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FGB | 3662 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FGD4 | 19125 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FGF11 | 3667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FGF11 | 3667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FGF2 | 3676 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| FGF2 | 3676 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| FGF5 | 3683 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FGF5 | 3683 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FGFBP1 | 19695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FGFBP1 | 19695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FGFR1 | 3688 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| FGFR1 | 3688 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| FGFR2 | 3689 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FGFR2 | 3689 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FGFR4 | 3691 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29316740
|
| FGG | 3694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FGG | 3694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FGL1 | 3695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FGL1 | 3695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FGL1 | 3695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FHL2 | 3703 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| FHOD3 | 26178 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FHOD3 | 26178 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FILIP1 | 21015 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FILIP1 | 21015 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FILIP1L | 24589 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FITM2 | 16135 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FJX1 | 17166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FKBP1A | 3711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| FKRP | 13949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FLI1 | 3749 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FLI1 | 3749 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FLOT2 | 3758 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| FLRT2 | 3761 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FLRT2 | 3761 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FLVCR1 | 24682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FLVCR1 | 24682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FLVCR1 | 24682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FLVCR2 | 20105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| FMNL1 | 1212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FOCAD | 23377 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FOCAD | 23377 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FOS | 3796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| FOXK1 | 23480 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| FREM1 | 23399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| FRMD3 | 24125 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| FRMD4B | 24886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FRMD4B | 24886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| FRMD6 | 19839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FRMD6 | 19839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FRYL | 29127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FRYL | 29127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FRYL | 29127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FRYL | 29127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| FSCN1 | 11148 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| FST | 3971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FST | 3971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FSTL1 | 3972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FSTL1 | 3972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FTL | 3999 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| FUT11 | 19233 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| FXYD2 | 4026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| FXYD3 | 4027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| FZD6 | 4044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| FZD6 | 4044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| FZR1 | 24824 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| G0S2 | 30229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| G0S2 | 30229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| G6PC3 | 24861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| G6PD | 4057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GAB1 | 4066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GAB1 | 4066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GABARAPL1 | 4068 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GABRA5 | 4079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GABRA5 | 4079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GABRB3 | 4083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| GABRB3 | 4083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GABRB3 | 4083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GADD45A | 4095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GALC | 4115 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GALM | 24063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| GALM | 24063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| GALM | 24063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| GALNT13 | 23242 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GALNT13 | 23242 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GALNT3 | 4125 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| GALNT3 | 4125 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| GALNT4 | 4126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GALNT4 | 4126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GALNT5 | 4127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GALNT5 | 4127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GALNT6 | 4128 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| GALNT6 | 4128 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| GALNT6 | 4128 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| GAS2L3 | 27475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| GATM | 4175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| GATM | 4175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| GBP1 | 4182 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GBP3 | 4184 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GBP3 | 4184 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GBP3 | 4184 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GBP6 | 25395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GBP6 | 25395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GC | 4187 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| GCA | 15990 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GCLC | 4311 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GCNT2 | 4204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GCNT2 | 4204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GCNT3 | 4205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GCNT3 | 4205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GCNT4 | 17973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GCNT4 | 17973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GDAP1 | 15968 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| GDAP1 | 15968 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GDF15 | 30142 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| GDPGP1 | 34360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GEM | 4234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GEMIN5 | 20043 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GEMIN6 | 20044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GFER | 4236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GGA2 | 16064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GGCX | 4247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GGT8P | 33438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GGTLC1 | 16437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GID8 | 15857 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GINS1 | 28980 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GINS2 | 24575 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GINS2 | 24575 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GINS2 | 24575 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GINS4 | 28226 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GJB1 | 4283 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| GJB2 | 4284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GJB2 | 4284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GJB5 | 4287 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GJB5 | 4287 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GJB6 | 4288 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GJC1 | 4280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GJC1 | 4280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GKAP1 | 17496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GKAP1 | 17496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GLA | 4296 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GLA | 4296 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GLDC | 4313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GLDC | 4313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GLDN | 29514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| GLG1 | 4316 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GLI3 | 4319 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GLI3 | 4319 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GLIPR1 | 17001 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GLIPR1 | 17001 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GLIS3 | 28510 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GLIS3 | 28510 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GLRX | 4330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GLT8D2 | 24890 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GLUL | 4341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GLUL | 4341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GLUL | 4341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GLYCTK | 24247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GM2A | 4367 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GM2A | 4367 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GNA15 | 4383 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GNA15 | 4383 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GNAI2 | 4385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GNAI2 | 4385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GNB4 | 20731 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GNE | 23657 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| GNG11 | 4403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GNG11 | 4403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GNL3L | 25553 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GOLGA2P2Y | 16479 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GOLGA2P5 | 25315 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| GOLPH3 | 15452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GOLPH3L | 24882 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GOPC | 17643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GOSR1 | 4430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GPAT3 | 28157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GPAT3 | 28157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GPATCH1 | 24658 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GPC6 | 4454 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GPC6 | 4454 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GPCPD1 | 26957 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GPD1L | 28956 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GPNMB | 4462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| GPR141 | 19997 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GPR160 | 23693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| GPR20 | 4475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GPR37L1 | 14923 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| GPR87 | 4538 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GPRC5A | 9836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| GPRC5B | 13308 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GPRIN3 | 27733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GPRIN3 | 27733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GPSM2 | 29501 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GPSM2 | 29501 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GPX2 | 4554 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GPX2 | 4554 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GPX3 | 4555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GPX3 | 4555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| GRAMD1B | 29214 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GRAMD1B | 29214 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GRAMD2B | 24911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| GRAMD2B | 24911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| GRB14 | 4565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GRB14 | 4565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GREB1 | 24885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| GRK5 | 4544 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GRK5 | 4544 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GRN | 4601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| GSDMC | 7151 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GSDMC | 7151 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| GSR | 4623 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GSR | 4623 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GSTA4 | 4629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| GSTM2 | 4634 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GSTM4 | 4636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GSTT2 | 4642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GSTT2 | 4642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GSTT2 | 4642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GSTT2B | 33437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GSTT2B | 33437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GSTT2B | 33437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| GTF3C2 | 4665 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GTPBP1 | 4669 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GUCA1B | 4679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GULP1 | 18649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GULP1 | 18649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| GYG2 | 4700 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GYG2 | 4700 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| GYG2P1 | 4701 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| GYS1 | 4706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| H1-1 | 4715 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| H1-1 | 4715 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| H1-3 | 4717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| H19 | 4713 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| H19 | 4713 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| H2AC17 | 4735 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29316740
|
| H2AC21 | 20508 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| H2AC4 | 4734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| H2BC12 | 13954 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| H2BC9 | 4755 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| H2BC9 | 4755 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| H3C11 | 4771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HABP2 | 4798 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
| HACD3 | 24175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HACD4 | 20920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HAVCR1 | 17866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| HAVCR1 | 17866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| HBB | 4827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| HBEGF | 3059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HBEGF | 3059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HCLS1 | 4844 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HCLS1 | 4844 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HDAC1 | 4852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| HDAC8 | 13315 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HEATR5A | 20276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HECW1 | 22195 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HEG1 | 29227 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| HELB | 17196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HEMK1 | 24923 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HEPACAM | 26361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| HEPHL1 | 30477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| HEPHL1 | 30477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| HERC3 | 4876 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HERC3 | 4876 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HERC5 | 24368 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HES1 | 5192 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
| HEXA | 4878 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| HEXA-AS1 | 25810 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HGD | 4892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HGD | 4892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HGD | 4892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HGD | 4892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HGSNAT | 26527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HHEX | 4901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HHEX | 4901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HHIP | 14866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HHIPL2 | 25842 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HHIPL2 | 25842 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HID1 | 15736 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HILPDA | 28859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| HIP1 | 4913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HIP1 | 4913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HIP1 | 4913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HIP1 | 4913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HIRIP3 | 4917 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HIVEP2 | 4921 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HIVEP2 | 4921 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HJURP | 25444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HK2 | 4923 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HKDC1 | 23302 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HKDC1 | 23302 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HLA-DMA | 4934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HLA-DMB | 4935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HLA-DMB | 4935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HLA-G | 4964 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-G | 4964 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HLA-J | 4967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HLA-J | 4967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HLTF | 11099 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HLTF | 11099 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HM13 | 16435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HMCN2 | 21293 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| HMGA2 | 5009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| HMGA2 | 5009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| HMGCR | 5006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| HMGCR | 5006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| HMGCS1 | 5007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| HMGCS1 | 5007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| HMGN2 | 4986 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HMGN5 | 8013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| HMOX1 | 5013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
| HMOX1 | 5013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| HMOX1 | 5013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| HMOX2 | 5014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HNF1A-AS1 | 26785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HNF1A-AS1 | 26785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HNF1B | 11630 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HNF1B | 11630 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HNF4G | 5026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HNRNPD | 5036 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HOOK2 | 19885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HOOK3 | 23576 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HORMAD1 | 25245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HORMAD1 | 25245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HOXA-AS3 | 43748 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HOXB6 | 5117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HOXB6 | 5117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HOXB6 | 5117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HOXB-AS3 | 40283 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HPGD | 5154 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| HPGD | 5154 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| HPSE | 5164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| HRAS | 5173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HRAS | 5173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HRAS | 5173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HRSP12 | 16897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HSD11B2 | 5209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| HSD17B11 | 22960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HSD17B11 | 22960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HSPA1A | 5232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| HSPA1A | 5232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| HSPA1B | 5233 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| HSPA2 | 5235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| HSPA4L | 17041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| HSPB1 | 5246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| HSPE1 | 5269 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| HSPG2 | 5273 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| HTATIP2 | 16637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HTATIP2 | 16637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HTR1D | 5289 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| HUWE1 | 30892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| HYKK | 34403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| HYKK | 34403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ID2 | 5361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| ID2 | 5361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| ID3 | 5362 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ID3 | 5362 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| IDH1-AS1 | 40292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IFFO2 | 27006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IFI16 | 5395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IFI16 | 5395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IFI30 | 5398 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| IFI35 | 5399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IFI44 | 16938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IFI44 | 16938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IFITM10 | 40022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| IFITM3 | 5414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IFITM3 | 5414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IFNE | 18163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IFNGR2 | 5440 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IFNL2 | 18364 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IFT20 | 30989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| IFT80 | 29262 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| IFT81 | 14313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| IFT81 | 14313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| IGF2 | 5466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| IGF2BP1 | 28866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| IGF2BP1 | 28866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| IGF2BP1 | 28866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| IGF2BP1 | 28866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| IGF2BP2 | 28867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IGF2BP2 | 28867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IGF2BP3 | 28868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
| IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
| IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
| IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
| IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 25881239
|
| IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 25881239
|
| IGFBP5 | 5474 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| IGFBP7 | 5476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IGFBP7 | 5476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IGIP | 33847 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IGLL1 | 5870 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IL16 | 5980 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IL16 | 5980 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IL17RA | 5985 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IL1A | 5991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| IL1A | 5991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 35229723
|
| IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 29416721
|
| IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| IL1R1 | 5993 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| IL1R1 | 5993 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| IL1RAP | 5995 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL1RAP | 5995 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL1RL1 | 5998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL1RL1 | 5998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL1RN | 6000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| IL1RN | 6000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| IL20RB | 6004 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL20RB | 6004 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL31RA | 18969 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL31RA | 18969 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL4R | 6015 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IL6R | 6019 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 18034892
|
| IL7R | 6024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IL7R | 6024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| IMPA2 | 6051 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29316740
|
| INA | 6057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| INA | 6057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| INAVA | 25599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| INF2 | 23791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ING3 | 14587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| INPP4B | 6075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| INPP4B | 6075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| INPP4B | 6075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| INPP5D | 6079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| INPP5D | 6079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| INPP5E | 21474 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| INPP5F | 17054 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| INSIG1 | 6083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| INSIG1 | 6083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| INSIG2 | 20452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| INS-IGF2 | 33527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| INS-IGF2 | 33527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| INSL4 | 6087 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| INSL4 | 6087 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| INTS2 | 29241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| INTS9 | 25592 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IQCA1 | 26195 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IQCA1 | 26195 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| IQCJ-SCHIP1 | 38842 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IQGAP2 | 6111 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| IQGAP2 | 6111 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| IQSEC2 | 29059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| IRAG2 | 6690 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IRAIN | 50365 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| IRAK3 | 17020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IRAK3 | 17020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| IREB2 | 6115 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| IRF6 | 6121 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| IRF6 | 6121 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| IRX5 | 14361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ISL1 | 6132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ISL1 | 6132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ITGA1 | 6134 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| ITGA10 | 6135 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| ITGA11 | 6136 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| ITGA2 | 6137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0106 | 25881239
|
| ITGA2 | 6137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0106 | 25881239
|
| ITGA2B | 6138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| ITGA3 | 6139 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ITGA3 | 6139 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ITGA5 | 6141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ITGA5 | 6141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ITGA6 | 6142 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0265 | 25881239
|
| ITGA6 | 6142 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0265 | 25881239
|
| ITGAD | 6146 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| ITGAL | 6148 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| ITGAX | 6152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| ITGB2 | 6155 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| ITGB2 | 6155 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| ITGB4 | 6158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 29416721
|
| ITGB4 | 6158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 29416721
|
| ITGB4 | 6158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| ITGB4 | 6158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| ITGB5 | 6160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ITGB5 | 6160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| ITGB6 | 6161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ITGB6 | 6161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| ITGB8 | 6163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 29416721
|
| ITGB8 | 6163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| ITGB8 | 6163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| ITGBL1 | 6164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ITGBL1 | 6164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ITLN1 | 18259 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ITPR3 | 6182 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ITPR3 | 6182 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| JADE1 | 30027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| JADE1 | 30027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| JADE2 | 22984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| JAG1 | 6188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 25881239
|
| JAG1 | 6188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 25881239
|
| JCAD | 29283 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| JMY | 28916 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| JPH1 | 14201 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| JPT1 | 14569 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| JPT2 | 14137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| KAAG1 | 21031 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| KANK3 | 24796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KAT2B | 8638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| KAT2B | 8638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| KATNAL1 | 28361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KATNB1 | 6217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KBTBD11-OT1 | 49147 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KCNC4 | 6236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KCNJ15 | 6261 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KCNJ15 | 6261 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KCNMA1 | 6284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| KCNQ5 | 6299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KCNQ5 | 6299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KCP | 17585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| KCTD14 | 23295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KCTD14 | 23295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KCTD21 | 27452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KEAP1 | 23177 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KIAA0040 | 28950 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| KIAA0040 | 28950 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| KIAA0319 | 21580 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| KIAA0319 | 21580 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| KIAA1217 | 25428 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KIAA1217 | 25428 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KIAA1614 | 29327 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KIF13B | 14405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| KIF18A | 29441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| KIF18A | 29441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| KIF27 | 18632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| KIF27 | 18632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| KIRREL1 | 15734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KIRREL1 | 15734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KLF5 | 6349 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| KLF6 | 2235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| KLF6 | 2235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| KLF6 | 2235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| KLF7 | 6350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KLF7 | 6350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KLHDC2 | 20231 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| KLHDC4 | 25272 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KLHL15 | 29347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| KLHL36 | 17844 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KMT2E | 18541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| KNG1 | 6383 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| KNOP1 | 34404 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| KRR1 | 5176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KRR1 | 5176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KRT14 | 6416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KRT14 | 6416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| KRT15 | 6421 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| KRT15 | 6421 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| KRT18 | 6430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
| KRT18 | 6430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
| KRT18 | 6430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
| KRT18 | 6430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
| KRT19 | 6436 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| KRT4 | 6441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 18034892
|
| KRT5 | 6442 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| KRT5 | 6442 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| KRT6A | 6443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| KRT6A | 6443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| KRT6A | 6443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| KRT6B | 6444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| KRT6B | 6444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| KRT6B | 6444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| KRT6C | 20406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| KRT7 | 6445 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| KRT81 | 6458 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| KRT81 | 6458 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| KRT81 | 6458 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| KRTAP10-10 | 22972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KRTAP1-3 | 16771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KRTAP1-4 | 18904 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KRTAP4-1 | 18907 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| KYAT3 | 33238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| KYNU | 6469 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| KYNU | 6469 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| LACTB2 | 18512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| LACTB2 | 18512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| LACTB2 | 18512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| LAD1 | 6472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| LAMA3 | 6483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| LAMA3 | 6483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| LAMA3 | 6483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| LAMA5 | 6485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LAMB3 | 6490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 29416721
|
| LAMB3 | 6490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| LAMB3 | 6490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| LAMC2 | 6493 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| LAMC2 | 6493 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| LAMC2 | 6493 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| LAPTM4B | 13646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LAPTM4B | 13646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LAPTM5 | 29612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LAPTM5 | 29612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LARS2 | 17095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LCLAT1 | 26756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| LCLAT1 | 26756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LDAH | 26145 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LDLR | 6547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LDLR | 6547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LENG9 | 16306 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LETR1 | 49597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LGALS1 | 6561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| LGALS3BP | 6564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
| LGR4 | 13299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| LGR4 | 13299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| LGR6 | 19719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
| LGSN | 21016 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LGSN | 21016 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LHFP | 6586 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LHFP | 6586 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LIFR | 6597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LIFR | 6597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LIMA1 | 24636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| LIMA1 | 24636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| LIMK2 | 6614 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LIN7A | 17787 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LIN7A | 17787 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LINC00265 | 28019 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC00294 | 27456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC00523 | 20117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC00540 | 43673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC00672 | 44353 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC00674 | 44355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC00842 | 44989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC00963 | 48716 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC00963 | 48716 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC01000 | 38541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC01433 | 50746 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC01475 | 51113 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC01535 | 51282 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LINC02908 | 31426 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LIPG | 6623 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LIPG | 6623 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LIPH | 18483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LIPH | 18483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LMAN1L | 6632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LMCD1 | 6633 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| LMLN | 15991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| LMNB1 | 6637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| LMO2 | 6642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LMO2 | 6642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LNCAROD | 50913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LNX2 | 20421 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LNX2 | 20421 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LOC728392 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LONP2 | 20598 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| LONRF2 | 24788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LONRF2 | 24788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LONRF3 | 21152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| LOX | 6664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
| LOXL2 | 6666 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| LPA | 6667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LPAR1 | 3166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| LPAR1 | 3166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| LPAR3 | 14298 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LPAR3 | 14298 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LPCAT2 | 26032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| LPCAT2 | 26032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| LPCAT2 | 26032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LPCAT4 | 30059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LPP | 6679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LPXN | 14061 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LPXN | 14061 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LRBA | 1742 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LRCH1 | 20309 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| LRFN1 | 29290 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LRIG1 | 17360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| LRIG1 | 17360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| LRIG1 | 17360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| LRIG1 | 17360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| LRIG3 | 30991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LRP6 | 6698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LRP6 | 6698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LRPPRC | 15714 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0064 | 18034892
|
| LRR1 | 19742 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| LRRC23 | 19138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LRRC37A2 | 32404 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LRRC37A3 | 32427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LRRC37A4P | 25479 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LRRC37B | 29070 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LRRC6 | 16725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LRRC8A | 19027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LRRC8C | 25075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LRRC8C | 25075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LRRK2 | 18618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LRRK2 | 18618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| LRRN2 | 16914 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| LSAMP | 6705 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| LSAMP | 6705 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| LTBP2 | 6715 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| LUCAT1 | 48498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| LUZP1 | 14985 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LUZP1 | 14985 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| LXN | 13347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| LXN | 13347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| LY75 | 6729 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LY75 | 6729 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| LYNX1 | 29604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MACsIR | 25052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MACsIR | 25052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MADD | 6766 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MAGI1 | 946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| MAGI1 | 946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| MAL2 | 13634 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| MALL | 6818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MALL | 6818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MAML2 | 16259 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MAML3 | 16272 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MAML3 | 16272 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MANF | 15461 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MANSC1 | 25505 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MAOA | 6833 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MAOA | 6833 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MAP1B | 6836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MAP1B | 6836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MAP1LC3B2 | 34390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MAP2 | 6839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MAP2K5 | 6845 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MAP2K6 | 6846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MAP2K6 | 6846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MAP3K14 | 6853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MAP3K14-AS1 | 44359 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MAP3K2 | 6854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MAP3K20 | 17797 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MAP3K21 | 29798 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MAP3K5 | 6857 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MAP7D2 | 25899 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MAP7D2 | 25899 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MAPK13 | 6875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MAPK13 | 6875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MAPK3 | 6877 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MAPK8IP2 | 6883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MAPKAPK3 | 6888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MAPKAPK3 | 6888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MAPKAPK5-AS1 | 24091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MARK1 | 6896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MARK1 | 6896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MARS1 | 6898 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MARVELD2 | 26401 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MAT2A | 6904 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MATN2 | 6908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MATN2 | 6908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MBD2 | 6917 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MBNL3 | 20564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MBOAT2 | 25193 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MBOAT2 | 25193 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MBTPS2 | 15455 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MBTPS2 | 15455 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MCAM | 6934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| MCAM | 6934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| MCC | 6935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MCC | 6935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MCM6 | 6949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MCM8 | 16147 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MCPH1 | 6954 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MCTP2 | 25636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MCTP2 | 25636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MDM4 | 6974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ME1 | 6983 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| MED13L | 22962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MED15 | 14248 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MEGF8 | 3233 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MEGF9 | 3234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MEGF9 | 3234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MEIOC | 26670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MEIOC | 26670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MEIS1 | 7000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MEIS1 | 7000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MEIS3P1 | 7002 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MEIS3P2 | 17638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MEST | 7028 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| METTL13 | 24248 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| METTL6 | 28343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| METTL7B | 28276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| METTL7B | 28276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MFAP5 | 29673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MFAP5 | 29673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MFF | 24858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MFN2 | 16877 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MFSD10 | 16894 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MFSD2A | 25897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MFSD2A | 25897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MFSD3 | 25157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MGAT1 | 7044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MGAT5 | 7049 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MGLL | 17038 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MGST2 | 7063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| MGST2 | 7063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| MGST3 | 7064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MIA2 | 18432 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MICAL2 | 24693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MICAL2 | 24693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MICALCL | 24693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MICALCL | 24693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MICU1 | 1530 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MID1 | 7095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MID1 | 7095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MIEN1 | 28230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MIF | 7097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MIR101-1 | 31488 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 31692042
|
| MIR129-1 | 31512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 31692042
|
| MIR17HG | 23564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MIR181A1 | 31590 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 31692042
|
| MIR198 | 31570 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MIR198 | 31570 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MIR200A | 31578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 33959615
|
| MIR205 | 31583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 31692042
|
| MIR205 | 31583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MIR205 | 31583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MIR208A | 31585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 33959615
|
| MIR20B | 32024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0042 | 22301433
|
| MIR221 | 31601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 33959615
|
| MIR222 | 31602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 33959615
|
| MIR224 | 31604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0042 | 22301433
|
| MIR27A | 31613 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 31692042
|
| MIR27A | 31613 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0053 | 22301433
|
| MIR27B | 31614 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0021 | 22301433
|
| MIR29B1 | 31619 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0064 | 22301433
|
| MIR29B2 | 31620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 31692042
|
| MIR29C | 31621 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 31692042
|
| MIR30B | 31625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 31692042
|
| MIR30B | 31625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 31692042
|
| MIR30B | 31625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0053 | 22301433
|
| MIR30C2 | 31627 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 31692042
|
| MIR30D | 31628 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 31692042
|
| MIR30E | 31629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0032 | 22301433
|
| MIR34C | 31637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 33959615
|
| MIR501 | 32135 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 33959615
|
| MIR504 | 32139 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 33959615
|
| MIR622 | 32878 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MIR622 | 32878 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MIR675 | 33351 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MIR675 | 33351 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MIR940 | 33683 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MIRLET7A1 | 31476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0032 | 22301433
|
| MIRLET7D | 31481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0021 | 22301433
|
| MIRLET7F2 | 31484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0021 | 22301433
|
| MLLT3 | 7136 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MLLT3 | 7136 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MLLT3 | 7136 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MLPH | 29643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MLXIP | 17055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MLYCD | 7150 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MMAA | 18871 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MMD | 7153 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MMD | 7153 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MMP1 | 7155 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MMP1 | 7155 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MMP10 | 7156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MMP10 | 7156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MMP14 | 7160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 35229723
|
| MMP14 | 7160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MMP14 | 7160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MMP2 | 7166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MMP24-AS1 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MMP25-AS1 | 51372 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MMP7 | 7174 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
| MNS1 | 29636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MOB3B | 23825 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MORC3 | 23572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MORC3 | 23572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MORC4 | 23485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MORC4 | 23485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MORC4 | 23485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MORC4 | 23485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MOSPD3 | 25078 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MOSPD3 | 25078 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MPC1 | 21606 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MPI | 7216 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MPP1 | 7219 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MPZL2 | 3496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| MPZL2 | 3496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| MPZL3 | 27279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| MREG | 25478 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MROH1 | 26958 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MROH1 | 26958 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MROH6 | 27814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MRPL12 | 10378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MRPL33 | 14487 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MRPL38 | 14033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MRPL4 | 14276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MRPL50 | 16654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MRPS35 | 16635 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MSH3 | 7326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MSH3 | 7326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MSH3 | 7326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MSH3 | 7326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MSH5 | 7328 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MSL3P1 | 17837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MSMO1 | 10545 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MSMO1 | 10545 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MST1 | 7380 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
| MST1R | 7381 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MST1R | 7381 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MT1DP | 7396 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MT1DP | 7396 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MT1E | 7397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MT1E | 7397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MT1F | 7398 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT1F | 7398 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT1G | 7399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MT1G | 7399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MT1L | 7404 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT1L | 7404 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT1P3 | 16120 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MT1P3 | 16120 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| MT1X | 7405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| MT1X | 7405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| MT1X | 7405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MTAP | 7413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MTAP | 7413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MTMR10 | 25999 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MTMR9 | 14596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MTSS1 | 20443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| MTSS1 | 20443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| MTUS1 | 29789 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MTUS1 | 29789 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MUC13 | 7511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| MUC13 | 7511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| MUC13 | 7511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| MUC5AC | 7515 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| MUC5B | 7516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| MUC5B | 7516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| MYBBP1A | 7546 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MYEF2 | 17940 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MYEF2 | 17940 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| MYEOV | 7563 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MYEOV | 7563 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MYH10 | 7568 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| MYLK | 7590 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| MYLK2 | 16243 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| MYO1D | 7598 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MYO1D | 7598 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| MYO1E | 7599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MYO1E | 7599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MYO6 | 7605 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| MYO9A | 7608 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| MYOCD | 16067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MYOCD | 16067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| MYZAP | 43444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| NABP1 | 26232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| NABP1 | 26232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| NAP1L2 | 7638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NAP1L2 | 7638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NAPA-AS1 | 44118 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NARG2 | 29885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NARG2 | 29885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NAV1 | 15989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NAV1 | 15989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NAV3 | 15998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| NAV3 | 15998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| NCAPD2 | 24305 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NCEH1 | 29260 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| NCF2 | 7661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NCOA1 | 7668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NCOA1 | 7668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NCOA2 | 7669 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NCOA3 | 7670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NCOA3 | 7670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NCOA7 | 21081 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NCOR1 | 7672 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NCOR1P1 | 16724 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NCRNA00250 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NDFIP2 | 18537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NDRG1 | 7679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| NDRG1 | 7679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| NDRG2 | 14460 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NDST1 | 7680 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NECTIN1 | 9706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NECTIN1 | 9706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NEDD9 | 7733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NEDD9 | 7733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NEFM | 7734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NEIL3 | 24573 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NEK1 | 7744 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NEK1 | 7744 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NEK2 | 7745 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NELFB | 24324 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NELL2 | 7751 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| NEO1 | 7754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NEO1 | 7754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NEURL4 | 34410 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| NEXN | 29557 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NF2 | 7773 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NFAT5 | 7774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NFATC2 | 7776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NFIC | 7786 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NFKB1 | 7794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| NFKB1 | 7794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| NFKBIZ | 29805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NFKBIZ | 29805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NFRKB | 7802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NFS1 | 15910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NFS1 | 15910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NGEF | 7807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NGEF | 7807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NHSL1 | 21021 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NIBAN1 | 16784 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| NICN1 | 18317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NINL | 29163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NIPAL1 | 27194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NIPAL1 | 27194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NIPAL2 | 25854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NIPAL2 | 25854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| NIPAL3 | 25233 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NIPAL4 | 28018 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NIPAL4 | 28018 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NIPSNAP1 | 7827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NIPSNAP1 | 7827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NKAP | 29873 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NKD1 | 17045 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NKRF | 19374 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NLN | 16058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| NLRP1 | 14374 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NLRP1 | 14374 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NLRP2 | 22948 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NLRP2 | 22948 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NME4 | 7852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NME4 | 7852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NME5 | 7853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NME5 | 7853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NMI | 7854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NMNAT1 | 17877 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NNMT | 7861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| NNMT | 7861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| NOC4L | 28461 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NOD2 | 5331 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NOP53 | 4333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29316740
|
| NOP9 | 19826 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NOSTRIN | 20203 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NOSTRIN | 20203 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NOXA1 | 10668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 35229723
|
| NPAS2 | 7895 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NPAS2 | 7895 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NPC1 | 7897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| NPC1 | 7897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| NPC2 | 14537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NPC2 | 14537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NPEPL1 | 16244 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NPR3 | 7945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NPR3 | 7945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NPR3 | 7945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NPR3 | 7945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NPW | 30509 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| NPY4R | 9329 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NPY4R | 9329 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NQO1 | 2874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| NQO1 | 2874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| NQO2 | 7856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NR0B1 | 7960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NR0B1 | 7960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 18034892
|
| NR1D1 | 7962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| NR1D1 | 7962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NR1D1 | 7962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NR2E3 | 7974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NR4A2 | 7981 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| NR4A3 | 7982 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NR5A2 | 7984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| NR5A2 | 7984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| NRAD1 | 26981 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| NRCAM | 7994 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NRCAM | 7994 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NREP | 16834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NRG4 | 29862 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NRG4 | 29862 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NRSN2 | 16229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NT5C2 | 8022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NT5DC2 | 25717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NT5E | 8021 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 25881239
|
| NT5E | 8021 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 25881239
|
| NTM | 17941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NTM | 17941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NTN1 | 8029 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| NTN4 | 13658 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NTRK3 | 8033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| NTRK3 | 8033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| NTRK3 | 8033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NTRK3 | 8033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NTS | 8038 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
| NTS | 8038 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NTS | 8038 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| NUDT11 | 18011 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| NUDT14 | 20141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NUDT6 | 8053 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NUDT6 | 8053 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NUDT7 | 8054 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| NUFIP1 | 8057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NUP210 | 30052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NUP210 | 30052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| NUP50-DT | 50502 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| NUP62CL | 25960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| NUP62CL | 25960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| OAS1 | 8086 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| OAS1 | 8086 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| OAS2 | 8087 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| OAT | 8091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| OAT | 8091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| OCIAD2 | 28685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| OCIAD2 | 28685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| OCIAD2 | 28685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| OCIAD2 | 28685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ODF2 | 8114 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ODF2L | 29225 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ODR4 | 24299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29316740
|
| OGDH | 8124 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ONECUT1 | 8138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| OPTN | 1941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OR2A4 | 14729 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OR2A4 | 14729 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OR2A7 | 8234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OR2A7 | 8234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OR2A7 | 8234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OR2A7 | 8234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OR7E156P | 31311 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| OR8B8 | 8477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ORAI3 | 28185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| OSBPL10 | 16037 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OSGEPL1-AS1 | 41009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| OSGIN2 | 1355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| OSGIN2 | 1355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| OSTF1 | 8510 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OSTF1 | 8510 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OVOL2 | 15804 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| OVOS2 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| OXCT1 | 8527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| OXCT1 | 8527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| P2RX4 | 8535 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| P3H2 | 19317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| P3H2 | 19317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| P4HA1 | 8546 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| P4HA2 | 8547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| P4HA2 | 8547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PABPC3 | 8556 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PABPC4 | 8547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PACS1 | 30032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PAFAH1B2 | 8575 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| PAK2 | 8591 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PAK3 | 8592 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PAK3 | 8592 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PALMD | 15846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PALMD | 15846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PANX1 | 8599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PANX1 | 8599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PAPPA | 8602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PAPPA | 8602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PAPPA | 8602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PAPSS1 | 8603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PAPSS2 | 8604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PAPSS2 | 8604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PAQR4 | 26386 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PAQR5 | 29645 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PAQR5 | 29645 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PARD3 | 29645 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PARD6B | 16245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PARM1 | 16245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PARP14 | 29232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PATZ1 | 14652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PAXIP1-DT | 27328 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PBX1 | 8632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| PBX1 | 8632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PBX1 | 8632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PCBD1 | 8646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PCBD1 | 8646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PCBP2 | 8648 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PCDH9 | 8661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PCDH9 | 8661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PCDHA1 | 8663 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| PCDHA1 | 8663 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| PCDHA4 | 8670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PCDHB5 | 8690 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PCDHB5 | 8690 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PCDHGA9 | 8707 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| PCDHGC4 | 8717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| PCED1A | 16212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PCF11 | 30097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PCLAF | 28961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PCLAF | 28961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PCOLCE2 | 8739 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PCOLCE2 | 8739 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PCYT1A | 8754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PDCD1LG2 | 18731 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PDCD1LG2 | 18731 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PDCD2L | 28194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PDE10A | 8772 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDE10A | 8772 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDE1C | 8776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDE1C | 8776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDE3A | 8778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PDE3A | 8778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PDE3B | 8779 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDE4B | 8781 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDE4B | 8781 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDE4D | 8783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| PDE4D | 8783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PDE4D | 8783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PDE4DIP | 15580 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PDE5A | 8784 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| PDE7B | 8792 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDE7B | 8792 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDE8A | 8793 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDE8A | 8793 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDE8B | 8794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDE8B | 8794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDGFC | 8801 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PDGFC | 8801 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PDGFD | 30620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDGFD | 30620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDGFRL | 8805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDGFRL | 8805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PDK1 | 8809 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| PDK1 | 8809 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| PDK2 | 8810 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PDK4 | 8812 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PDK4 | 8812 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PDP1 | 9279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PDP1 | 9279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PDPK1 | 8816 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| PDPN | 29602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| PDPN | 29602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PDPN | 29602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PEA15 | 8822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PEAK1 | 29431 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PECAM1 | 8823 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| PECR | 18281 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PECR | 18281 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PEG10 | 14005 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PEG10 | 14005 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PELI1 | 8827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PELI1 | 8827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PELI2 | 8828 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PELO | 8829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| PEPD | 8840 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PER2 | 8846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PERP | 17637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PEX3 | 8858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PFKFB3 | 8874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PGBD3 | 19400 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PGBD3 | 19400 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PGD | 8891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| PGD | 8891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| PGD | 8891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| PGM2 | 8906 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PGM2 | 8906 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PGS1 | 30029 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PHACTR2 | 20956 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PHF11 | 17024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PHF16 | 22982 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PHF21A | 24156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PHF21B | 25161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PHLDA1 | 8933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PHLDA1 | 8933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PHOSPHO1 | 16815 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PHTF1 | 8939 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PHYH | 8940 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PI3 | 8947 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
| PI4K2B | 18215 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PI4KA | 8983 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PIGM | 18858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PIGU | 15791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PIK3CD | 8977 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PILRA | 20396 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PIP | 8993 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PIP4K2B | 8998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PIR | 30048 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PIR | 30048 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PJVK | 29502 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PKDCC | 25123 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PKP1 | 9023 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PKP2 | 9024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PKP2 | 9024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PKP4 | 9026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PLA2G4A | 9035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| PLA2G4A | 9035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PLA2G4A | 9035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PLA2R1 | 9042 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PLAAT3 | 17825 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PLAAT3 | 17825 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PLAT | 9051 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| PLAU | 9052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| PLAU | 9052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PLAU | 9052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PLBD1 | 26215 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PLCB1 | 15917 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLCB3 | 9056 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PLCB4 | 9059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PLCE1 | 17175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLCE1 | 17175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLCH1 | 29185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PLCH1 | 29185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PLD1 | 9067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLD1 | 9067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLD5 | 26879 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLD5 | 26879 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLEK2 | 19238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PLEK2 | 19238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PLEKHH2 | 30506 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PLIN2 | 248 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
| PLOD1 | 9081 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| PLPP1 | 9228 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLPPR1 | 25993 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PLS3-AS1 | 50343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PLSCR3 | 16495 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PLSCR3 | 16495 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PLSCR4 | 16497 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PLXNA1 | 9099 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PLXNA1 | 9099 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PLXNA2 | 9100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PLXNA2 | 9100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PLXNA2 | 9100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PLXNC1 | 9106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| PMP22 | 9118 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PMP22 | 9118 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PNMA8A | 25578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PNPLA2 | 30802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PNRC2 | 23158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PNRC2 | 23158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| POC1B | 30836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| POC1B | 30836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PODXL | 9171 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| POF1B | 13711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| POF1B | 13711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| POLA1 | 9173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| POLA2 | 30073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLD1 | 9175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLD2 | 9176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLD4 | 14106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLH | 9181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| POLH | 9181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| POLM | 9185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLQ | 9186 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| POLR1A | 17264 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLR1D | 20422 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| POLR1G | 24219 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| POLR2C | 9189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLR2E | 9192 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLR2F | 9193 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLR2G | 9194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| POLR2L | 9199 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PON2 | 9205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PON2 | 9205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PON3 | 9206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PON3 | 9206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| POP1 | 30129 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PORCN | 17652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PORCN | 17652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PPARD | 9235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PPARD | 9235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PPARG | 9236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PPARG | 9236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PPFIBP2 | 9250 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PPIEL | 33195 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PPIL6 | 21557 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PPM1B | 9276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PPM1B | 9276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PPM1B | 9276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PPME1 | 30178 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PPP1R10 | 9284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PPP1R13L | 18838 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PPP1R14A | 14871 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PPP1R18 | 29413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PPP1R18 | 29413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PPP1R21 | 30595 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PPP1R9A | 14946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PPP2R2A | 9304 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PPP2R2C | 9306 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PPP2R2C | 9306 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PPP2R3A | 9307 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PPP2R3A | 9307 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PPP4R1 | 9320 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PPP4R1 | 9320 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PPP4R4 | 23788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PPP4R4 | 23788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PQLC2 | 26001 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PRAME | 9336 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PRAME | 9336 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PRDX1 | 9352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PREP | 9358 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PREP | 9358 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PRG4 | 9364 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PRIM1 | 9369 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PRKAA2 | 9377 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PRKAR1B | 9390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PRKAR2B | 9392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PRKAR2B | 9392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PRKCA | 9393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PRKCA | 9393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PRKCE | 9401 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PRKD1 | 9407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PRKD1 | 9407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PRKDC | 9413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| PRMT6 | 18241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PRMT6 | 18241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PROS1 | 9456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PROS1 | 9456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PROS1 | 9456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PROS1 | 9456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PRPS1 | 9462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PRR11 | 25619 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| PRR12 | 29217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PRR14 | 28458 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PRSS12 | 9477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PRSS12 | 9477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PRSS2 | 9483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PRSS2 | 9483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PRSS2 | 9483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PRSS27 | 15475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PRSS3P2 | 43788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PRTFDC1 | 23333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PRTFDC1 | 23333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| PRTG | 26373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PRTG | 26373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PSIP1 | 9527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PSMC4 | 9551 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PSMC4 | 9551 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PSMD2 | 9559 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PSME3 | 9570 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PSMF1 | 9571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PSPH | 9577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PSPH | 9577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PSTPIP2 | 9581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PSTPIP2 | 9581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PTAFR | 9582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PTAFR | 9582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PTCH1 | 9585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PTCH1 | 9585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PTER | 9590 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PTGES3L-AARSD1 | 43946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PTGES3L-AARSD1 | 43946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PTGFRN | 9601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PTGFRN | 9601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PTGR1 | 18429 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PTGR1 | 18429 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PTGR2 | 20149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PTPN13 | 9646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PTPN13 | 9646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PTPN14 | 9647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PTPN14 | 9647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PTPN18 | 9649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PTPRD | 9668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| PTPRE | 9669 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PTPRE | 9669 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| PTPRG | 9671 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PTPRG | 9671 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PTPRJ | 9673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PTPRJ | 9673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PTPRJ | 9673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| PTPRK | 9674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PTPRK | 9674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| PTPRM | 9675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PTPRM | 9675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| PTPRZ1 | 9685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PTPRZ1 | 9685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| PVR | 9705 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PVRIG | 32190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| PVT1 | 9709 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| PXDN | 14966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PXDN | 14966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| PYGO1 | 30256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| PYGO1 | 30256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| QPCT | 9753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| QSOX1 | 9756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| QSOX1 | 9756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| R3HDM2 | 29167 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RAB11FIP1 | 30265 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| RAB11FIP3 | 17224 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RAB15 | 20150 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RAB15 | 20150 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RAB31 | 9771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| RAB31 | 9771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| RAB37 | 30268 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RAB38 | 9776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RAB38 | 9776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RAB4B | 9782 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RABEP2 | 24817 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RABL2A | 9799 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RAC1 | 9801 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| RAC2 | 9802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RAC2 | 9802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RAD50 | 9816 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RAD54B | 17228 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RAET1E | 16793 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RAF1 | 9829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RAF1 | 9829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RAF1 | 9829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RALA | 9839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RALB | 9840 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| RALB | 9840 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| RAP1GDS1 | 9859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RAP1GDS1 | 9859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RAP2A | 9861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RAPH1 | 14436 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| RAPH1 | 14436 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| RAPH1 | 14436 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| RARA | 9864 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RARB | 9865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| RARB | 9865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| RARB | 9865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| RARB | 9865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| RARRES1 | 9867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RASAL2 | 9874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RASAL2 | 9874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RASD1 | 15828 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RASD1 | 15828 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RASEF | 26464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| RASEF | 26464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| RASEF | 26464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| RASSF2 | 9883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RASSF6 | 20796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RBBP8 | 9891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RBBP8 | 9891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RBFA | 26120 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RBFOX3 | 27097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RBM24 | 21539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RBM24 | 21539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RBM47 | 30358 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RBMS1 | 9907 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RBMS3 | 13427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RBMX | 9910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RBMXL1 | 25073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RBP1 | 9919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RBP1 | 9919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RBP4 | 9922 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RBP4 | 9922 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RBPMS | 19097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| RBPMS | 19097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| RBX1 | 9928 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RCCD1 | 30457 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RDH10 | 19975 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| RECQL4 | 9949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| REPIN1 | 17922 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RESF1 | 25559 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RET | 9967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| REX1BD | 26098 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RFC1 | 9969 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| RFC5 | 9973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RFK | 30324 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RFPL1 | 9977 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RFPL2 | 9979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RFTN1 | 30278 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RFTN1 | 30278 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RGS2 | 9998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RHBDL2 | 16083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RHCG | 18140 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| RHNO1 | 28206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RHOBTB1 | 18738 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RHOBTB1 | 18738 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RHOD | 670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| RHOD | 670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| RHOQ | 17736 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RHOT1 | 21168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RHOT1 | 21168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RHOT1 | 21168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RHOU | 17794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RHPN1 | 19973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RHPN2 | 19974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RHPN2 | 19974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RIC3 | 30338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RIOK3 | 11451 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RIPK2 | 10020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RMI1 | 25764 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RNASE4 | 10047 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| RND1 | 18314 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RNF103 | 12859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RNF122 | 21147 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RNF144B | 21578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| RNF144B | 21578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| RNF152 | 26811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RNF152 | 26811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RNF157 | 29402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| RNF157 | 29402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| RNF157 | 29402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| RNF19B | 26886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RNF217-AS1 | 50866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RNF32-DT | 48971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RNFT2 | 25905 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RNH1 | 10074 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RNPEP | 10078 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RNU6ATAC5P | 34095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29316740
|
| ROR1 | 10256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ROR1 | 10256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RPAIN | 28641 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RPAIN | 28641 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RPGR | 10295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RPL31P11 | 35849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RPP25L | 19909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RPRD1B | 16209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RPS12 | 10385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29316740
|
| RPS27L | 18476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RPS27L | 18476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RPS6KA1 | 10430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| RPS6KA3 | 10432 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RPS6KA6 | 10435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| RPS6KA6 | 10435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RPS6KA6 | 10435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RRNAD1 | 24273 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RRP7BP | 30454 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29316740
|
| RSKR | 26314 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RSPO3 | 20866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RSPO3 | 20866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| RSRC1 | 24152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| RTN3 | 10469 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RTN4IP1 | 18647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RTN4IP1 | 18647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| RUNX2 | 10472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| RUNX2 | 10472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| S100A14 | 18901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
| S100A14 | 18901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| S100A14 | 18901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| S100A16 | 20441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| S100A16 | 20441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| S100A2 | 10492 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| S100A2 | 10492 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| S100A4 | 10494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
| S100A4 | 10494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
| S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
| S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 29416721
|
| S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| S100A9 | 10499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
| S100P | 10504 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0106 | 34059086
|
| S100P | 10504 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 25881239
|
| S1PR1 | 3165 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| SAA1 | 10513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SAA1 | 10513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SACS | 10519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| SACS | 10519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SAMD1 | 17958 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SAMD9 | 1348 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SAMD9 | 1348 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SARS2 | 17697 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SARS2 | 17697 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SAT1 | 10540 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
| SATB2 | 21637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SAYSD1 | 21025 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SC5DL | 10547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SC5DL | 10547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SCAF4 | 19304 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SCCPDH | 24275 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SCFD2 | 30676 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29316740
|
| SCGB3A1 | 18384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SCML2 | 10581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SCML2 | 10581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SCN9A | 10597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SCNN1A | 10599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| SCO1 | 10603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SDC4 | 10661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SDC4 | 10661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SDC4P | 18903 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SDCBP2 | 15756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SDF2 | 10675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SDHA | 10680 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
| SDR42E1 | 29834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SDR42E1 | 29834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SEBOX | 32942 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| SEC14L2 | 10699 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SEC14L2 | 10699 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SEC16A | 29006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SEC16B | 30301 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SEC24D | 10706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SEL1L3 | 29108 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SELENOP | 10751 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| SELENOW | 10752 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SELPLG | 10722 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| SEMA3A | 10723 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SEMA3A | 10723 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SEMA4F | 10734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SEMA4F | 10734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SEMA7A | 10741 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SEMA7A | 10741 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SERINC2 | 23231 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SERINC2 | 23231 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SERINC5 | 18825 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SERPINB1 | 3311 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| SERPINB2 | 8584 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SERPINB2 | 8584 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SERPINB3 | 10569 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| SERPINB5 | 8949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| SERPINB5 | 8949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| SERPINB8 | 8952 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SERPINB8 | 8952 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SERPINB9 | 8955 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SERPINB9 | 8955 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SERPINE1 | 8583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| SERPINE1 | 8583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| SERPINE2 | 8951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SERPINE2 | 8951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SERPINF1 | 8824 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SERPINF1 | 8824 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SERTAD1 | 17932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SERTAD4 | 25236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SESN3 | 23060 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SETD1A | 29010 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SF3B3 | 10770 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SFI1 | 29064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SFMBT2 | 20256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| SFMBT2 | 20256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| SFN | 10773 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| SFN | 10773 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| SFRP1 | 10776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SFRP1 | 10776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SFRP4 | 10778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SFRS3 | 10785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 18034892
|
| SGCA | 10805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SGCD | 10807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SGCD | 10807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SGCE | 10808 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SGCE | 10808 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SGK3 | 10812 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SGMS2 | 28395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SH2D4A | 26102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| SH2D4A | 26102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SH3BGRL | 10823 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| SH3BGRL3 | 15568 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SH3PXD2A | 23664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| SH3PXD2A | 23664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| SH3RF2 | 26299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SH3RF2 | 26299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SHARPIN | 25321 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SIDT1 | 25967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SIGLEC11 | 15622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| SIGLEC16 | 24851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| SIPA1L1 | 20284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SIPA1L1 | 20284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SIPA1L2 | 23800 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SIRPB2 | 16247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SIRPG-AS1 | 51229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SIRT1 | 14929 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SIRT1 | 14929 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SIRT3 | 14931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SIRT5 | 14933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SIRT5 | 14933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SIRT6 | 14934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SIRT7 | 14935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SKAP2 | 15687 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SKI | 10896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SKP2 | 10901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| SLAIN1 | 26387 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC10A7 | 23088 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC10A7 | 23088 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC12A2 | 10911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| SLC12A2 | 10911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| SLC16A2 | 10923 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC16A4 | 10925 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC16A9 | 23520 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC1A3 | 10941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SLC20A1 | 10946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC20A1 | 10946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC20A2 | 10947 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC20A2 | 10947 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC22A15 | 20301 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC22A3 | 10967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC22A3 | 10967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC23A1 | 10974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLC23A2 | 10973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC23A2 | 10973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC25A1 | 10979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SLC25A30 | 27371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC25A42 | 28380 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SLC26A10 | 14470 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC27A2 | 10996 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SLC27A2 | 10996 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SLC28A2 | 11002 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
| SLC29A1 | 11003 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SLC2A1 | 11005 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SLC2A1 | 11005 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SLC2A3 | 11007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| SLC2A3 | 11007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| SLC2A9 | 13446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC30A7 | 19306 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC31A2 | 11017 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC31A2 | 11017 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC37A2 | 20644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC37A2 | 20644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC38A5 | 18070 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC38A5 | 18070 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC38A6 | 19863 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLC38A6 | 19863 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLC39A11 | 14463 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC40A1 | 10909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC40A1 | 10909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC41A2 | 31045 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC41A2 | 31045 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC43A1 | 9225 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SLC43A3 | 17466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC43A3 | 17466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC44A2 | 17292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC44A2 | 17292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC44A3-AS1 | 49057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SLC45A4 | 29196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC45A4 | 29196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC47A1 | 25588 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SLC47A1 | 25588 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SLC4A3 | 11029 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SLC4A4 | 11030 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| SLC4A4 | 11030 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SLC4A4 | 11030 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SLC52A2 | 30224 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SLC5A11 | 23091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SLC5A6 | 11041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SLC5A6 | 11041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SLC5A6 | 11041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLC66A3 | 28503 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC6A10P | 11043 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC6A10P | 11043 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC6A11 | 11044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC6A11 | 11044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC6A15 | 13621 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC6A16 | 13622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC6A6 | 11052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC6A6 | 11052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC6A8 | 11055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC6A8 | 11055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC7A11 | 11059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLC7A2 | 11060 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLC7A2 | 11060 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLC7A5P2 | 24951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 31692042
|
| SLC7A7 | 11065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC7A7 | 11065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC7A8 | 11066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SLC8A1 | 11068 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SLC8A2 | 11069 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SLC9A1 | 11071 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC9A1 | 11071 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SLC9A2 | 11072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC9A2 | 11072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLC9A3R1 | 11075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SLC9B2 | 25143 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLC9B2 | 25143 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLCO1B3 | 10961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLCO1B3 | 10961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SLF1 | 25408 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLF1 | 25408 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SLFN12 | 25500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLFN12 | 25500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLFN5 | 28286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SLMAP | 16643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SLPI | 11092 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
| SLX4IP | 16225 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SMARCA1 | 11097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SMARCA1 | 11097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SMARCA4 | 11100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SMCR6 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SMG1P1 | 44186 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 31692042
|
| SMIM14 | 27321 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SMIM31 | 49638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SMOX | 15862 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SMOX | 15862 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SMTN | 11126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SMURF2 | 16809 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SMURF2 | 16809 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SNAI2 | 11094 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0159 | 25881239
|
| SNAI2 | 11094 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0159 | 25881239
|
| SNAP25 | 11132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SNAP25 | 11132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SNAPC5 | 15484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SNAPC5 | 15484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SNCA | 11138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SNCA | 11138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SNED1 | 24696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| SNHG11 | 25046 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SNHG12 | 30062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SNORA11 | 32599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29316740
|
| SNORA61 | 32655 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SNORA70D | 34356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SNORA75 | 32661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SNORA78 | 32664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SNORD14C | 30352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SNORD36B | 10164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SNORD41 | 10179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29316740
|
| SNORD42B | 10181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SNORD42B | 10181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SNORD4A | 10097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SNORD4B | 10098 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SNORD4B | 10098 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SNORD75 | 32735 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SNORD91A | 32752 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SNRNP25 | 14161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SNX29 | 30542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SOCS6 | 16833 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SOCS6 | 16833 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SOGA3 | 21494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SORBS1 | 14565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| SORL1 | 11185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SORL1 | 11185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SOWAHC | 26149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SOWAHC | 26149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SOX21 | 11197 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
| SOX8 | 11203 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
| SP1 | 11205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SP100 | 11206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SP2 | 11207 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SPAG5 | 13452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SPARC | 11219 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SPARC | 11219 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SPATA17 | 25184 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SPATA18 | 29579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SPCS3 | 26212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SPCS3 | 26212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SPIDR | 28971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SPINT1 | 11246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SPINT1 | 11246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SPOCK1 | 11251 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SPOCK1 | 11251 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SPOCK2 | 13564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SPON1 | 11252 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| SPP1 | 11255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| SPP1 | 11255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SPR | 11257 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SPR | 11257 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SPRR1B | 11260 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SPRR1B | 11260 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SPTLC3 | 16253 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SPTSSA | 20361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| SPX | 28139 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SQLE | 11279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SQOR | 20390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SQOR | 20390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| SQSTM1 | 11280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| SRCIN1 | 29506 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| SREK1IP1 | 26716 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SREK1IP1 | 26716 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SRGN | 9361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SRGN | 9361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SRPX | 11309 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SRPX | 11309 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| SRPX2 | 30668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| SRSF2 | 10783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SRXN1 | 16132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SRXN1 | 16132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SRXN1 | 16132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SRXN1 | 16132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| SSBP2 | 15831 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SSBP3 | 15674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SSH2 | 30580 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ST14 | 11344 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ST3GAL6 | 18080 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ST6GAL2 | 10861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ST6GAL2 | 10861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ST6GALNAC2 | 10867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ST6GALNAC2 | 10867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ST8SIA4 | 10871 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| ST8SIA4 | 10871 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| STAB1 | 18628 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| STARD3 | 17579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| STARD4 | 18058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| STARD4 | 18058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| STARD5 | 18065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| STARD5 | 18065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| STARD5 | 18065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| STAT1 | 11362 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| STEAP1 | 11378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| STEAP1 | 11378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| STEAP2 | 17885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| STIMATE | 30526 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| STING1 | 27962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| STK11 | 11389 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| STK17A | 11395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| STK17A | 11395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| STK32B | 14217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| STK32B | 14217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| STK35 | 16254 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| STN1 | 26200 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| STRADB | 13205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| STRBP | 16462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| STRIP2 | 22209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| STRN | 11424 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| STX6 | 11441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| STXBP4 | 19694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| STXBP4 | 19694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SUCLA2 | 11448 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SULF2 | 20392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SULF2 | 20392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| SULT1C2 | 11456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| SUMO3 | 11124 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SYCP2 | 11490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
| SYK | 11491 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SYK | 11491 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| SYNM | 24466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SYNM | 24466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SYT1 | 11509 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| SYT17 | 24119 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SYT17 | 24119 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| SYT3 | 11511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| SYT7 | 11514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| SYTL1 | 15584 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
| SYTL1 | 15584 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| SZRD1 | 30232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TAC3 | 11521 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
| TACC2 | 11523 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TACO1 | 24316 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TACSTD2 | 11530 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| TAGLN3 | 29868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TAGLN3 | 29868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TANC2 | 30212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TAOK1 | 29259 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TBC1D1 | 11578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TBC1D1 | 11578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TBC1D15 | 25694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TBC1D2 | 18026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TBC1D2 | 18026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TBC1D30 | 29164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TBC1D31 | 30888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TBC1D31 | 30888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TBC1D8 | 17791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TBX18 | 11595 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TBX18 | 11595 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TBX3 | 11602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| TBX4 | 11603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TCEA1 | 11612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TCEA1 | 11612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TCF7 | 11639 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TCF7L1 | 11640 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TCIM | 1357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TCIM | 1357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TCOF1 | 11654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| TCP11L2 | 28627 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TEAD4 | 11717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TEC | 11719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TECTA | 11720 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TENM2 | 29943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TENM2 | 29943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TERT | 11730 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| TERT | 11730 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| TESC | 26065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TESC | 26065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TET1 | 29484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TEX9 | 29585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TFAP2C | 11744 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TFDP1 | 11749 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TFDP2 | 11751 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TFF1 | 11755 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TFG | 11758 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TFPI | 11760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TFPI | 11760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TFPI2 | 11761 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| TFPI2 | 11761 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| TGFA | 11765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TGFA | 11765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TGFBR3 | 11774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TGFBR3 | 11774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| THBS1 | 11785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| THBS1 | 11785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| THRA | 11796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| THRA | 11796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| THSD4 | 25835 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| THSD7A | 22207 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| THSD7A | 22207 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TICRR | 28704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TIGD1 | 14523 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TIGD5 | 18336 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TIMELESS | 11813 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TIMM10 | 11814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TIMP1 | 11820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| TIMP1 | 11820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| TIMP2 | 11821 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TIMP2 | 11821 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TIMP3 | 11822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| TIMP3 | 11822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| TIMP3 | 11822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| TIMP3 | 11822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| TINAG | 14599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| TINAG | 14599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| TINAGL1 | 19168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TINAGL1 | 19168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TIPARP | 23696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TIPARP | 23696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TIPARP | 23696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TIPIN | 30750 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TJP2 | 11828 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TKT | 11834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| TKT | 11834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| TLCD1 | 25177 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TLCD1 | 25177 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TLCD2 | 33522 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TLCD4 | 26477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TLCD4 | 26477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TLE1 | 11837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TLE1 | 11837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TLNRD1 | 13519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TLR3 | 11849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TLR4 | 11850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TLR4 | 11850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TLR5 | 11851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TLR6 | 16711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TLR6 | 16711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TM4SF1 | 11853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| TM4SF1 | 11853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| TM4SF1 | 11853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0053 | 18034892
|
| TM4SF1 | 11853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0053 | 18034892
|
| TM4SF18 | 25181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TM4SF18 | 25181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TM4SF20 | 26230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TM4SF20 | 26230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TMBIM1 | 23410 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TMC6 | 18021 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMC7 | 23000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMC8 | 20474 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMCC3 | 29199 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TMCO3 | 20329 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMCO4 | 27393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMEFF2 | 11867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TMEM106B | 22407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TMEM115 | 30055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMEM120B | 32008 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TMEM145 | 26912 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TMEM147 | 30414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TMEM154 | 26489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMEM154 | 26489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMEM156 | 26260 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TMEM167B | 30187 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMEM167B | 30187 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMEM171 | 27031 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TMEM176B | 29596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMEM184B | 1310 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMEM185B | 18896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMEM198B | 43629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMEM2 | 11869 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TMEM205 | 29631 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TMEM225B | 53075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMEM230 | 15876 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TMEM30B | 27254 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TMEM40 | 25620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TMEM40 | 25620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TMEM43 | 28472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TMEM43 | 28472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TMEM45A | 25480 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| TMEM45A | 25480 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
| TMEM45B | 25194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| TMEM50B | 1280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMEM54 | 24143 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TMEM60 | 21754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TMEM63B | 17735 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMEM63C | 23787 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TMEM87A | 24522 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TMEM97 | 28106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| TMEM97 | 28106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TMEM97 | 28106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TMEM97 | 28106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TMPO | 11875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TMPRSS11D | 24059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMPRSS11D | 24059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TMPRSS7 | 30846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TMUB2 | 28459 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TNC | 5318 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TNC | 5318 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TNF | 11892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TNFAIP1 | 11894 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TNFAIP3 | 11896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| TNFAIP3 | 11896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
| TNFRSF10A | 11904 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TNFRSF1A | 11916 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TNFRSF4 | 11918 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TNFSF10 | 11925 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TNFSF10 | 11925 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TNFSF13 | 11928 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TNFSF15 | 11931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TNIP1 | 16903 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TNIP1 | 16903 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TNNT1 | 11948 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TNNT1 | 11948 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TNS3 | 21616 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TNS3 | 21616 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TNS4 | 24352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| TNS4 | 24352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
| TOM1L1 | 11983 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TOMM22 | 18002 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TOMM34 | 15746 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TOP1MT | 29787 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TOP2B | 11990 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TOX3 | 11972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| TOX3 | 11972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TP53 | 11998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TP53I3 | 19373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 29316740
|
| TP53I3 | 19373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| TP53INP1 | 18022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29316740
|
| TP63 | 15979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TP63 | 15979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TPBG | 12004 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| TPBG | 12004 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
| TPD52L1 | 12006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| TPD52L2 | 12007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TPM2 | 12011 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TPM4 | 12013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
| TPST1 | 12020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TPST1 | 12020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TRAF3IP2 | 1343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TRAF3IP2 | 1343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TRAF4 | 12034 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TRAF4 | 12034 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TRAM2 | 16855 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TRAPPC1 | 19894 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TRERF1 | 18273 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TRIM14 | 16283 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TRIM16 | 17241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TRIM16 | 17241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TRIM16L | 32670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TRIM16L | 32670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TRIM22 | 16379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TRIM25 | 12932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TRIM29 | 17274 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| TRIM29 | 17274 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
| TRIML2 | 26378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TRIML2 | 26378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| TRIOBP | 17009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TRIP13 | 12307 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| TRMT10A | 28403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TRMT10A | 28403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TRMT10C | 26022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TRMT10C | 26022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TRO | 12326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
| TRPA1 | 497 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TRPA1 | 497 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TRPS1 | 12340 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TRPS1 | 12340 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TSC2 | 12363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TSKU | 28850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TSPAN1 | 20657 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TSPAN1 | 20657 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| TSPAN5 | 17753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TSPAN5 | 17753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TSPAN6 | 11858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| TSPAN6 | 11858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| TSTD1 | 35410 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TSTD1 | 35410 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TTBK2 | 19141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TTC39B | 23704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TUBA4A | 12407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TUBB4A | 20774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TUBB4A | 20774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TUBB6 | 20776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| TUBD1 | 16811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TUBD1 | 16811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TUBGCP4 | 16691 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| TUBGCP6 | 18127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| TXNIP | 16952 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
| TXNRD1 | 12437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| TXNRD1 | 12437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| U2AF1L4 | 23020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UAP1 | 12457 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UAP1 | 12457 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UBA1 | 12469 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
| UBA2 | 30661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| UBA2 | 30661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| UBA6 | 25581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UBA6 | 25581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UBALD2 | 28438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| UBB | 12463 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UBE2C | 15937 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| UBE2E3 | 12479 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| UBR1 | 16808 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UBTF | 12511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| UBXN11 | 30600 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UCHL1 | 12513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| UCHL3 | 12515 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UCN2 | 18414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| UCP2 | 12518 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UCP2 | 12518 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UFSP1 | 33821 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| UGCG | 12524 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| UGCG | 12524 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| UGDH | 12525 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
| UGT2B7 | 12554 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UGT2B7 | 12554 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UGT8 | 12555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UGT8 | 12555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| UHRF1BP1 | 21216 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UNC93B1 | 13481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| UNG | 12572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
| UPF3B | 20439 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UPK1B | 12578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UPK1B | 12578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UPP1 | 12576 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| UPP1 | 12576 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| UQCRFS1 | 12587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| UQCRFS1 | 12587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| URI1 | 13236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| USP11 | 12609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| USP11 | 12609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| USP11 | 12609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| USP3 | 12626 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| USP35 | 20061 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| USP7 | 12630 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| VAMP8 | 12647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| VAPA | 12648 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| VASP | 12652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| VASP | 12652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| VAT1 | 16919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| VAV2 | 12658 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| VCAN | 2464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
| VCAN | 2464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| VCAN | 2464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| VCPIP1 | 30897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| VDR | 12679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| VDR | 12679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| VEGFA | 12680 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| VEGFA | 12680 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| VEGFC | 12682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| VEGFC | 12682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| VGLL3 | 24327 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| VGLL3 | 24327 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| VIL1 | 12690 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 35229723
|
| VPS37B | 25754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| VSIG8 | 32063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| VSNL1 | 12722 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| VSNL1 | 12722 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| VSTM2A | 28499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| VTI1B | 17793 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| WASF2 | 12733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| WASHC5 | 28984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| WASHC5 | 28984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| WDFY2 | 20482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| WDFY2 | 20482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| WDR17 | 16661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| WDR17 | 16661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| WDR35 | 29250 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| WDR35 | 29250 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| WDR47 | 29141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| WDR47 | 29141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| WDR72 | 26790 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| WDR72 | 26790 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| WDR77 | 29652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| WDR77 | 29652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| WDR91 | 24997 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| WIPI1 | 25471 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| WLS | 30238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| WLS | 30238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| WNT7A | 12786 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| WNT7A | 12786 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| XAGE1A | 4111 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| XAGE1A | 4111 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| XDH | 12805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| XDH | 12805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| XPC | 12816 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| XPNPEP3 | 28052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| XPO6 | 19733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| XPO7 | 14108 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| YAF2 | 17363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| YTHDC2 | 24721 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZBED2 | 20710 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZBED2 | 20710 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZBTB20 | 13503 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZBTB20 | 13503 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZBTB48 | 4930 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZC2HC1C | 20354 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZC3HAV1 | 23721 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZDHHC3 | 18470 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZFAND5 | 13008 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZFAND5 | 13008 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZFAND6 | 30164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZFHX4 | 30939 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZFHX4 | 30939 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZFP36L1 | 1107 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ZFP36L2 | 1108 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZFP41 | 26786 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ZFPM1 | 19762 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZKSCAN2 | 25677 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF146 | 12931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF146 | 12931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF181 | 12971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF185 | 12976 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ZNF185 | 12976 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ZNF185 | 12976 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ZNF20 | 12992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF20 | 12992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF215 | 13007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF253 | 13497 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF260 | 13499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF267 | 13060 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 18034892
|
| ZNF275 | 13069 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF28 | 13073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF280A | 18597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF280A | 18597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF280C | 25955 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF30 | 13090 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF30 | 13090 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF302 | 13848 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF302 | 13848 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF331 | 15489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF385A | 17521 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF397 | 18818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
| ZNF426 | 20725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF426 | 20725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF461 | 21629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF462 | 21684 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF468 | 33105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF468 | 33105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF486 | 20807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF486 | 20807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF507 | 23783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF507 | 23783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF512 | 29380 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF518A | 29009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF518A | 29009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF528 | 29384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF528 | 29384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF532 | 30940 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF558 | 26422 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF561 | 28684 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF566 | 25919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF566 | 25919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF567 | 28696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 18034892
|
| ZNF569 | 24737 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF574 | 26166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF618 | 29416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF625 | 30571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF625 | 30571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF626 | 30461 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF630 | 28855 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ZNF641 | 31834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ZNF649 | 25741 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ZNF671 | 26279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ZNF688 | 30489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF696 | 25872 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF711 | 13128 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF724 | 32460 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF728 | 32463 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF766 | 28063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
| ZNF780A | 27603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF780A | 27603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
| ZNF787 | 26998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZNF790 | 33114 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF790 | 33114 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF808 | 33230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF808 | 33230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF83 | 13158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF83 | 13158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF860 | 34513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ZNF860 | 34513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
| ZNF90 | 13165 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF90 | 13165 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF91 | 13166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF91 | 13166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZNF93 | 13169 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZNF93 | 13169 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
| ZSCAN20 | 13093 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
| ZSWIM9 | 34495 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZXDB | 13199 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
| ZYX | 13200 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
| ZZEF1 | 29027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|